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Regulation of Luteinizing Hormone and Catecholamine Release 
Abstract 
These studies tested the interrelated hypotheses that the ovarian hormones produce their positive 
feedback effects on luteinizing hormone (LH) secretion through activation of noradrenergic and 
adrenergic systems in specific hypothalamic regions. Furthermore, the ovarian hormones may alter the 
activity of opioid neuropeptide and Gamma-Aminobutyric Acid (GABA) systems to produce these 
alterations in catecholamine transmission and gonadotropin secretion. Radioimmunoassays were utilized 
to determine plasma LH and median eminence LHRH, and hypothalamic catecholamine concentrations 
were measured by radioenzymatic assay. 
The first two studies tested whether epinephrine (EPI) synthesis inhibition blocks the accumulation of 
median eminence LHRH that precedes the ovarian hormone-induced LH surge and also to test whether 
the stimulatory ovarian hormone regimen enhances the activity of hypothalamic EPI systems. 
Ovariectomized rats were primed with estradiol (EB), followed 2 days later by progesterone (Prog.). 
Animals were treated before Prog, administration with saline, one of the EPI synthesis inhibitors SKF 
64139 or LY 78335, or the norepinephrine (NE) synthesis inhibitor, FLA-63. The catecholamine synthesis 
inhibitors blocked or delayed the LH surge. FLA-63 completely prevented the accumulation of LHRH in the 
median eminence that preceded the rise in LH release. However, selective reduction in EPI levels with SKF 
64139 only partially prevented this increase in LHRH. A second EPI synthesis inhibitor, LY 78335, delayed 
both the LH surge and the rise in LHRH. 
In a second experiment, the administration of EB plus Prog, to ovariectomized rats increased the alpha-
methyltyrosine (aMT) induced depletion of EPI in the medial basal hypothalamus (MBH). The depletion of 
NE after synthesis inhibition was enhanced in both the MBH and preoptic-anterior hypothalamus (POA). 
Experiments 3 and 4 examined a possible mechanism underlying these ovarian hormone effects on LH 
release and catecholamine activity. These studies tested whether the opiate antagonist, naloxone, which 
increases LH release, enhances the activity of NE and EPI neurons in the hypothalamus, and also tested 
whether morphine, an opiate agonist which decreases LH release, depresses the activity of hypothalamic 
NE and EPI activity. Administration of naloxone to EB-primed rats increased LH release and potentiated 
the depletion of NE in the POA and MBH, and enhanced the decline of EPI and dopamine (DA) in the MBH, 
suggesting increased catecholamine activity in these regions. Administration of the opiate agonist, 
morphine, to rats pretreated with EB and Prog., decreased LH and decreased the depletion of the 
catecholamines in the POA and MBH, suggesting reduced activity. In most cases, naloxone antagonized 
the inhibitory effect of morphine. 
Experiments 3, 6, and 7 examined the involvement of (GABA) systems in the positive feedback effects of 
EB and Prog, on LHRH and LH release. These studies tested 1) the effects of GABAergic drugs on the LH 
surge induced by EB and Prog., 2) whether GABA agonists reduce NE and EPI activity in the 
hypothalamus, and 3) whether a GABA agonist prevents the accumulation of median eminence LHRH 
induced by EB and Prog. Ovariectomized rats received the stimulatory EB plus Prog, treatment. 
Simultaneously with Prog., rats received either saline, the barbiturate, phenobarbital, the GABAg agonist, 
baclofen, the GABA^ agonist, muscimol, or either the GABA^ antagonist, bicuculline, or the putative 
GABAg antagonist, 5-aminovalerate. Additional experiments tested the effects of the GABA drugs on LH 
release in ovariectomized, hormonally untreated rats and in response to exogenous LHRH. The LH surge 
induced by EB+Prog. was blocked by treatment with either baclofen, muscimol, or phenobarbital. 
Bicuculline was ineffective in preventing the effect of baclofen and phonobarbital but partially prevented 
the effect of muscimol. Neither baclofen nor muscimol significantly affected LH release in hormonally 
untreated, ovariectomized rats or in rats receiving LHRH administration. In the results of Experiment 6, in 
EB plus Prog.-treated rats, baclofen and muscimol significantly reduced the concentrations of EPI and NE 
in the POA and MBH and prevented their decline after administration of otMT, suggesting decreased 
catecholamine transmission. 
In Experiment 7, rats were primed with the ovarian hormones and received, concurrently with Prog., either 
saline, or baclofen. The GABAg agonist, baclofen, blocked the LH surge and selectively increased LHRH 
concentrations. 
Experiment 8 tested 1) whether baclofen reverses the enhancement of LH release and catecholamine 
activity produced by naloxone, and 2) whether the opiate antagonist, nalmefene, prevents the blockade of 
the LH surge produced by baclofen. In the first study of Experiment 8, naloxone increased LH release and 
enhanced catecholamine activity in EB-primed rats. Baclofen was unable to reverse these effects. In the 
second study, baclofen administration to EB plus P treated rats blocked the LH surge and concomitant 
administration of nalmefene was unable to prevent this effect of baclofen. 
These results suggest that: 1) the ovarian hormones activate both NE and EPI systems to stimulate the 
early afternoon rise of LHRH in the median eminence and to induce the subsequent LH surge, 2) the 
ovarian hormones may produce their positive feedback effects on LH secretion by removing an inhibitory 
GABA or opioid neuropeptide influence on catecholamine transmission, allowing NE and EPI to stimulate 
LHRH, and subsequently, LH release, and 3) these modulatory actions of GABA and opiates may represent 
effects of two parallel, yet independent hypothalamic systems which regulate catecholamine 
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ABSTRACT
These studies tested the interrelated hypotheses that the ovarian 
hormones produce their positive feedback effects on luteinizing hormone 
(LH) secretion through activation of noradrenergic and adrenergic sys­
tems in specific hypothalamic regions. Furthermore, the ovarian hor­
mones may alter the activity of opioid neuropeptide and Gamma-Amino­
butyric Acid (GABA) systems to produce these alterations in catechola­
mine transmission and gonadotropin secretion. Radioimmunoassays were 
utilized to determine plasma LH and median eminence LHRH, and hypotha­
lamic catecholamine concentrations were measured by radioenzymatic 
assay.
The first two studies tested whether epinephrine (EPI) synthesis 
inhibition blocks the accumulation of median eminence LHRH that precedes 
the ovarian hormone-induced LH surge and also to test whether the stimu­
latory ovarian hormone regimen enhances the activity of hypothalamic EPI 
systems. Ovariectomized rats were primed with estradiol (EB), followed 
2 days later by progesterone (Prog.). Animals were treated before 
Prog, administration with saline, one of the EPI synthesis inhibitors 
SKF 64139 or LY 78335, or the norepinephrine (NE) synthesis inhibitor, 
FLA-63. The catecholamine synthesis inhibitors blocked or delayed the 
LH surge. FLA-63 completely prevented the accumulation of LHRH in the 
median eminence that preceded the rise in LH release. However, selec­
tive reduction in EPI levels with SKF 64139 only partially prevented 
this increase in LHRH. A second EPI synthesis inhibitor, LY 78335, 
delayed both the LH surge and the rise in LHRH.
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In a second experiment, the administration of EB plus Prog, to 
ovariectomized rats increased the alpha-methyltyrosine (aMT) induced 
depletion of EPI in the medial basal hypothalamus (MBH). The depletion 
of NE after synthesis inhibition was enhanced in both the MBH and pre­
optic-anterior hypothalamus (POA).
Experiments 3 and 4 examined a possible mechanism underlying these 
ovarian hormone effects on LH release and catecholamine activity. These 
studies tested whether the opiate antagonist, naloxone, which increases 
LH release, enhances the activity of NE and EPI neurons in the hypotha­
lamus, and also tested whether morphine, an opiate agonist which 
decreases LH release, depresses the activity of hypothalamic NE and EPI 
activity. Administration of naloxone to EB-primed rats increased LH 
release and potentiated the depletion of NE in the POA and MBH, and 
enhanced the decline of EPI and dopamine (DA) in the MBH, suggesting 
increased catecholamine activity in these regions. Administration of 
the opiate agonist, morphine, to rats pretreated with EB and Prog., 
decreased LH and decreased the depletion of the catecholamines in the 
POA and MBH, suggesting reduced activity. In most cases, naloxone anta­
gonized the inhibitory effect of morphine.
Experiments 3, 6, and 7 examined the involvement of (GABA) systems 
in the positive feedback effects of EB and Prog, on LHRH and LH 
release. These studies tested 1) the effects of GABAergic drugs on the 
LH surge induced by EB and Prog., 2) whether GABA agonists reduce NE and 
EPI activity in the hypothalamus, and 3) whether a GABA agonist prevents
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the accumulation of median eminence LHRH induced by EB and Prog. 
Ovariectomized rats received the stimulatory EB plus Prog, treatment. 
Simultaneously with Prog., rats received either saline, the barbiturate, 
phenobarbital, the GABAg agonist, baclofen, the GABA^ agonist, 
muscimol, or either the GABA^ antagonist, bicuculline, or the putative 
GABAg antagonist, 5-aminovalerate. Additional experiments tested the 
effects of the GABA drugs on LH release in ovariectomized, hormonally 
untreated rats and in response to exogenous LHRH. The LH surge induced 
by EB+Prog. was blocked by treatment with either baclofen, muscimol, or 
phenobarbital. Bicuculline was ineffective in preventing the effect of 
baclofen and phonobarbital but partially prevented the effect of 
muscimol. Neither baclofen nor muscimol significantly affected LH 
release in hormonally untreated, ovariectomized rats or in rats 
receiving LHRH administration. In the results of Experiment 6, in EB 
plus Prog.-treated rats, baclofen and muscimol significantly reduced the 
concentrations of EPI and NE in the POA and MBH and prevented their 
decline after administration of otMT, suggesting decreased catecholamine 
transmission.
In Experiment 7, rats were primed with the ovarian hormones and 
received, concurrently with Prog., either saline, or baclofen. The 
GABAg agonist, baclofen, blocked the LH surge and selectively 
increased LHRH concentrations.
Experiment 8 tested 1) whether baclofen reverses the enhancement of 
LH release and catecholamine activity produced by naloxone, and 2)
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whether the opiate antagonist, nalmefene, prevents the blockade of the 
LH surge produced by baclofen. In the first study of Experiment 8, 
naloxone increased LH release and enhanced catecholamine activity in 
EB-primed rats. Baclofen was unable to reverse these effects. In the 
second study, baclofen administration to EB plus P treated rats blocked 
the LH surge and concomitant administration of nalmefene was unable to 
prevent this effect of baclofen.
These results suggest that: 1) the ovarian hormones activate both 
NE and EPI systems to stimulate the early afternoon rise of LHRH in the 
median eminence and to induce the subsequent LH surge, 2) the ovarian 
hormones may produce their positive feedback effects on LH secretion by 
removing an inhibitory GABA or opioid neuropeptide influence on cate­
cholamine transmission, allowing NE and EPI to stimulate LHRH, and sub­
sequently, LH release, and 3) these modulatory actions of GABA and opi­
ates may represent effects of two parallel, yet independent hypothalamic 
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REVIEW OF THE LITERATURE
A. Introduction
The estrous cycle of the female rat is characterized by the secre­
tion of both ovarian (estrogen, progesterone) and adenohypophyseal 
(luteinizing hormone, follicle stimulating hormone, prolactin) hormones 
which are released in a specific pattern. Plasma concentrations of 
luteinizing hormone (LH) and prolactin are maintained at low levels dur­
ing diestrus day 1 and 2 (1,2). This tonic inhibition is interrupted on 
proestrus by an afternoon surge in plasma levels of LH, follicle stimu­
lating hormone, and prolactin (1,2,3). These changes in anterior pitu­
itary secretion are the result of the negative (inhibitory) and positive 
(stimulatory) feedback effects of estradiol and progesterone (4). The 
feedback actions of the ovarian hormones could take place either in the 
brain or the pituitary (4,5).
B. Regulation of LH secretion by ovarian hormones
Circulating levels of estradiol and progesterone fluctuate during 
the estrous cycle (2). Progesterone, secreted by the corpora lutea, 
rises during estrus and diestrus I and decreases during diestrus II. 
Estradiol secretion also begins to increase on diestrus I and II. Such 
concentrations of estradiol act synergistcally with progesterone to pro­
vide the tonic inhibition of LH during diestrus (21,22). The acute 
increase in LH release following ovariectomy and the ability of estra­
diol to suppress it, support such a tonic inhibitory role for estradiol
1
2
during diestrus (57). Estradiol concentrations continue to rise 
continuously before peaking on proestrus morning (2, 3). That such high 
levels of estradiol are essential for the occurrence of the preovulatory 
LH surge is suggested by studies in which an estrogen antagonist (23) or 
estradiol antiserum (24,25) prevented the proestrous LH surge.
Estradiol thus appears to be indispensible for the proestrus LH surge to 
occur, however, progesterone may not be since antiserum to progesterone 
failed to block ovulation (24). However, progesterone does play an 
important role, in combination with estradiol, to augment the proestrus 
surge of LH (22,25).
Administration of ovarian hormones to ovariectomized rats can mimic 
the inhibitory and stimulatory actions seen during the estrous cycle. 
Following ovariectomy, plasma LH rises and is secreted in a pulsatile 
fashion (7,8), most probably a consequence of pulsatile LHRH release 
(18). Estradiol administration rapidly suppresses pulsatile LH release 
in ovariectomized rats (9,10) thus providing a reliable model of estra­
diol negative feedback effects. Ovariectomized rats treated with estra­
diol exhibit daily afternoon surges of LH (10,11) and progesterone 
administration to such rats markedly stimulates the LH surge (12).
These stimulatory effects of the ovarian hormones have provided a model 
of ovarian hormone positive feedback.
LHRH is the primary neural hormone regulating anterior pituitary LH 
release (13). LHRH cell bodies are concentrated in the diagonal band of 
Broca, septal nucleus, and preoptic area (14,15) and project fibers to
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the median eminence that terminate on blood vessels of the portal system 
of the pituitary (16,17).
LHRH appears to undergo fluctuations in rates of release during the 
course of the estrous cycle (18) with greatest amounts of LHRH released 
on proestrus (18,19). In fact, LHRH release during proestrus has 
recently been observed to of biphasic (18), with, an initial "priming" 
pulse followed 2-3 hours later (1600— 1730 hours) by a much larger 
secretion of LHRH. This priming action of LHRH significantly enhances 
the responsiveness of pituitary gonadotropes. Thus, a smaller quantity 
of LHRH may be required to initiate the LH surge (4,20) and LHRH release 
is then coordinated with enhanced pituitary responsiveness (4,20).
LHRH release appears to be responsive to changes in ovarian hormone 
concentrations during the estrous cycle. Estradiol increases LHRH 
release, both in vivo and in vitro (46,58). In addition, progesterone 
appears to have positive effects on LHRH synthesis and release (53,54, 
55).
After release of LHRH into the pituitary portal system, LHRH inter- 
binds to specific, high affinity membrane receptors to stimulate LH 
release from anterior pituitary gonadotroph cells (225). Ovarian hor­
mone manipulation of LHRH may account, at lease in part, for the effects 
of these hormones on LH release. In support of this, the increase in 
plasma LH levels observed after ovariectomy may be the result of an 
enhanced output of LHRH into the portal system (26,27). Moreover, the 
administration of estradiol, which suppresses pituitary LH secretion,
also depresses levels of LHRH In portal plasma of ovariectomized rats 
(26).
C. Locus of Action of Ovarian Hormones in Regulation of LH secretion:
1. Sites of negative feedback
The inhibitiory effects of estradiol on LH release are believed to 
occur in both the pituitary and the brain, especially the medial basal 
hypothalamus (MBH) (5). Results from several lines of investigation 
support the MBH as a site of estradiol's negative feedback: (1) estrogen 
and/or progesterone bind to and are taken up by diencephalic cells, 
including cells in the MBH (38), (2) implants of estradiol into the MBH 
depress LH release (27,32), (3) MBH lesions block estrogen's inhibition 
of LH in ovariectomized female rats (30), (4-) electrical stimulation of 
the MBH depresses episodic LH release (31), and (5) damage to the MBH 
from bilateral knife cuts suppresses pulsatile LH release (33). These 
observations suggest, therefore, that at least a part of estradiol's 
inhibitory effects on LH release may occur in the MBH.
Although the importance of progesterone in providing tonic inhibi­
tion of LH release during the estrous cycle has been established (22), 
the site of progesterone's inhibitory effects is not clear. Implants of 
progesterone into the MBH (29) or peripheral administration of the hor­
mone (36) causes inhibition of LH release.
Estradiol appears to also exert part of its negative feedback
effect on the pituitary gland. The response of the pituitary gland to
release LH following LHRH administration is acutely enhanced by ovariec-
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tomy (33). Moreover, estradiol reduces pituitary responsiveness to LHRH 
in ovariectomized rats (37,39).
In contrast to a report of enhanced LHRH neurosecretion accompany­
ing the post-ovariectomy increase in LH (26), other investigators (18, 
40) have failed to demonstrate any increase in portal plasma LHRH levels 
after ovariectomy. These results would suggest that estradiol produces 
its inhibitory effects on LH by acting on the pituitary gland. In 
further support of the anterior pituitary as the primary site of estra­
diol's negative feedback effects, a recent report (41) observed that a 
dose of estradiol that inhibits LH release, stimulates estrogen receptor 
translocation in the pituitary gland but not in the MBH. These results 
suggest that estradiol exerts its inhibitory effects on LH secretion by 
acting in the brain but perhaps mainly in the anterior pituitary.
2. Sites of positive feedback
The majority of experimental evidence supports the concept that the 
stimulatory effects of estradiol on LH release are exerted both in the 
brain and at the level of the pituitary gland (5). Within the brain, 
the preoptic area (POA) appears to be the most sensitive area to estra­
diol's effects. Estradiol is taken up by neurons in the POA (38) and 
electrochemical excitation of (42) or implantation of estradiol into 
(43,44) the POA stimulates LH release. In addition, damage to the POA 
by knife cuts reduces gonadotropin secretion (45). Estradiol's stimula­
tory effects on LH secretion may be due to stimulation of LHRH release 
(46). LHRH levels in the portal blood are enhanced on the afternoon of 
proestrous (18,19) and this has been attributed to an effect of
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increased estradiol concentrations (46). Moreover, estradiol stimulates 
the release of LHRH in vitro from the MBH of ovariectomized rats (58).
A portion of estradiol's positive feedback effects may occur in the 
pituitary gland (5). Estrogen increases the responsiveness of the pitu­
itary to LHRH after pituitary stalk section (47) and also increases res­
ponsiveness of pituitary cells to LHRH in vitro (48). However, the pos­
sibility that the enhanced pituitary responsiveness is due to increasd 
LHRH release and to augmented "priming" actions of LHRH can not be 
excluded (26).
The stimulatory effects of progesterone may also occur in the brain 
or pituitary. Progesterone (probably in combination with estradiol) 
stimulates LH secretion on the afternoon of proestrous (12,52).
Implants of progesterone into the MBH at 1000 hours on proestrous leads 
to ovulation (51). Administration of progesterone to ovariectomized 
rats primed with estradiol increases the concentration of LHRH in the 
MBH (53) and enhances the secretion of LHRH into the pituitary portal 
system (54). In addition, in estradiol--primed rats, progesterone 
stimulates the release of LHRH both in vivo and in vitro (55,56).
Stimulatory effects of progesterone have also been demonstrated in 
the POA. Implantation of progesterone into the POA-anterior hypothala­
mic area (226) elevates LH release in estrogen-primed, ovariectomized 
rats. Thus, progesterone appears to act in both the MBH and POA to 
induce LH release. Progesterone may also produce part of its stimula­
tory effects on LH release by an action on the anterior pituitary gland 
(5). Progesterone enhances the responsiveness of the pituitary gland to
LHRH (49,50). However, the possibility can not be excluded that 
enhanced pituitary responsiveness by progesterone to LHRH may be due to 
increased LHRH release or augmented "priming" action of LHRH (26).
D. Mechanism of Action of Ovarian Hormones
The mechanism of action of the ovarian hormones in producing their 
feedback effects may be by direct interaction with nerve cell membranes 
or by indirect actions at the level of the genome (59). An indirect 
mechanism of action of the ovarian steroids at the genomic level would 
involve an interaction of the hormone with its receptor to alter RNA 
synthesis and gene transcription (60). Steroid hormones diffuse freely 
into cells and are retained due to binding to receptor sites found only 
in target cells (61). This hormone-receptor complex then migrates to 
the nucleus and binds there to nuclear acceptor sites (61). The nuclear 
acceptor sites are composed largely of chromatin, a mixture of DNA and 
DNA-nonhistone protein complexes (61,62). After binding to the nuclear 
acceptor complex, the hormone is capable of altering RNA synthesis 
(61,62).
The possibility that the ovarian hormones may alter genomic func­
tion to produce their feedback effects is supported by observations that 
these hormones affect the levels of specific enzyme and neurotransmitter 
receptor proteins in the brain (63). Estrogen receptors have been 
demonstrated in the brain, especially concentrated in areas thought to 
be involved in the regulation of LH secretion, e.g. the POA and MBH (38, 
64). Estrogen treatment can alter the levels of enzymes, such as cho­
line acetyltransferase, acetylcholinesterase, glutamic acid decarboxy­
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lase, tyrosine hydroxylase, and type A monoamine oxidase that regulate 
neurotransmitter biosynthesis and degradation (59,63). Estrogen has 
also been shown to be able to induce progestin receptors in the POA (65) 
and to increase the number of muscarinic cholinergic, B— adrenergic, and 
serotonin type 1 receptors (63). However, whether these effects of 
estradiol are the result of genomic action and what role they play in 
ovarian hormone feedback remains undetermined.
Other lines of evidence do lend support to the concept that a por­
tion of ovarian hormone feedback action is at the genomic level. The 
effect of estradiol in inducing hypothalamic progestin receptors is 
blocked by the protein synthesis inhibitor, anisomycin (63). Moreover, 
microapplication of anisomycin to ventral medial hypothalamus prevents 
the activation of feminine sexual behavior induced by estradiol and pro­
gesterone (65). Estradiol activated RNA polymerase II in the hypothala­
mus (60) and recent evidence indicates that estradiol--induced receptor 
translocation in the pituitary and POA can be correlated to estradiol's 
negative and positive feedback effects, respectively (41).
Estradiol may produce a portion or all of its feedback actions by 
mechanisms other than classical receptor mechanisms. Estradiol could 
have direct effects on all membranes of LHRH neurons, catecholamine neu­
rons, or pituitary gonadotrope cells and thereby regulate gonadotropin 
secretion. In support of this concept, estradiol induces Ca++ dependent 
action potentials (66) and stimulates prolactin release (67) from cloned 
pituitary cells. Estradiol also stereospecifically hyperpolarizes POA 
and MBH neurons by a direct membrane effect (68) and although the iden­
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tity of the neurotransmitter/neuropeptide contained in these neurons is 
unknown, some of the neurons may contain LHRH (69). Thus, estradiol 
may produce its negative and positive feedback effects by either direct 
effects in the brain or on the pituitary and/or indirect effects 
mediated at a genomic level in these tissues.
E. Role of Catecholamines in Regulation of LH Secretion
1. General considerations
The catecholamines, dopamine, norepinephrine, and epinephrine are 
synthesized from the amino acid tyrosine (70). An active transport 
mechanism transports tyrosine into the nerve terminal where the enzyme 
tyrosine hydroxylase converts tyrosine to 3,4-— dihydroxyphenylalanine 
(DOPA), the formation of which appears to be the rate limiting step in 
catecholamine biosynthesis (71). Tyrosine hydroxylase is a stereo­
specific enzyme that requires a tetrahydropterine cofactor, in addition 
to Fe++ and molecular 02 (70). Alpha methyl--p--tyrosine, a competitive 
inhibitor of tyrosine, is an effective inhibitor of this enzymatic 
step. A carboxyl group is removed from DOPA by the enzyme L-aromatic 
amino acid decarboxylase, a non-specific enzyme requiring pyridoxal 
phosphate (72), to form dopamine (DA). DA is then transported, via a 
Mg*+--ATP dependent process, into storage granules where it is stored 
until conversion to norepinephrine (NE) (70). DA is converted to NE by 
the enzyme dopamine--B--hydroxylase (DBH) in an enzymatic process 
requiring ascorbate and molecular oxygen. DBH is a Cu++--containing 
protein and copper chelating agents, e.g. FLA--63, are very effective
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inhibitors of this enzyme (70). NE in the brain and adrenal medulla is 
subsequently methylated by the enzyme phenylethanolamine--N--methyl 
transferase (PNMT) to form epinephrine (EPI) in a reaction that uses S- 
adenosyl methionine as a methyl donor (73). Several competitive inhibi­
tors of PNMT including SK & F 64-139 and LY 78335 effectively inhibit EPI 
synthesis and consequently lower EPI concentrations in the brain tissue 
(74).
Following calcium--dependent release of either DA, NE, or EPI into 
the synaptic cleft, the catecholamine acts on specific receptors located 
on the effector cells. Multiple receptors on which the catecholamines 
act to produce their effects have been implicated for DA (D1 & D2) (75), 
and NE and EPI (alpha 1, alpha 2, beta 1, beta 2), (76,77). In addition 
to these post--synaptic receptors, abundant evidence indicates the pre­
sence of pre— synaptic receptors on catecholamine neurons that are 
involved in regulation of neurotransmitter release (78).
Pre--synaptic receptors involved in regulation of neurotransmitter 
release could include autoreceptors for the transmitter the neuron 
released, in addition to receptors for NE, DA, EPI, serotonin, angioten­
sin II, opioid peptides, acetylcholine, and prostaglandins (78).
The majority of NE, DA, or EPI released by nerve impulses is taken 
back up into the nerve terminals by an active re--uptake process (79). 
After re--uptake, catecholamines are degraded by two main enzymes, mono­
amine oxidase (MAO) and catechol--methyltransferase (COMT). Most of the 
release of NE and EPI that escapes re-uptake is metabolized by COMT to 
noremetanephrine and metanephrine, respectively (80). Normetanephrine
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and metanephrine are converted by MAO to 3-methoxy-4-hydroxy-mandelic 
acid (VMA), the major metabolite of catecholamines excreted in the urine 
(70). MAO and COMT, in addition to aldehyde reductase and dehydrogen­
ase, converts NE to 3,4 dihydroxyphenylglycol, 3,4 dihydroxyphenylethyl- 
glycol, and 3-methoxy-4-hydroxy-phenylglycol (80). DA also be converted 
to 3,4-dihydroxyphenylacetic acid by MAO and aldehyde dehydrogenase be­
fore being metylated by COMT to homovanillic acid (80).
The anatomical pathways of the catecholaminergic systems have been 
extensively analyzed (81,82). The noradrenergic system can be divided 
into the dorsal tegmental pathway and the ventral tegmental pathway 
(81). The dorsal tegmental pathway arises from cell bodies of the locus 
coeruleus (A6) (83) and projects primarily to the cerebral cortex, 
hippocampus, hypothalamus, and cerebellum (81). The ventral tegmental 
pathway originates from A1,2,5,7 cell groups and innervates the 
hypothalamus, thalamus, brainstem (81).
The adrenergic systems have been termed C1 and C2 and are similar 
in many respects to cell groups A1 and A2 of the noradrenergic system. 
Cell bodies of the adrenergic system appear to originate in the lateral 
reticular nucleus (C1) and rostral medulla near the nucleus of the soli­
tary tract (C2) (84). Adrenergic projections have been observed in the 
hypothalamus, thalamus, lower brainstem and intermediolateral cell 
column of the spinal cord (84).
The dopaminergic systems of the brain can be divided into nigros- 
triatal, mesocortical, incertohypothalamic, periventricular, and tubero- 
hypophyseal pathways. The dopaminergic pathways provide DA to a variety
12
of brain regions including the striatum, isocortex, allocortex, median 
eminence and pituitary, septum, and dorsal and pariventricular 
hypothalamic areas (82).
2. Catecholamine Involvement in Episodic LH release
Available evidence indicates an inhibitory role for DA in episodic 
LH secretion in the rat (85). DA and DA agonists such as apomorphine 
reduce LH release in ovariectomized rats (86,87,88). The inability of 
DA antagonists such as pimozide to affect LH release (87) has prompted 
the suggestion that DA is not a major regulator of steady state pulsa­
tile LH release (85).
In the rat, there appears to be a dual noradrenergic regulation of 
pulsatile LH release, i.e. both inhibitory and excitatory components 
have been described (85). Infusion of NE or clonidine intraventrtcu- 
iarly to ovariectomized rats suppresses episodic LH release (88,89). 
However, an excitatory noradrenergic system may also participate in 
regulating pulsatile LH release. Reduction of hypothalamic NE levels 
(86,87) or blockade of NE receptors (90) inhibits episodic LH release. 
The physiological significance of such a dual system in regulating epi­
sodic LH release in ovariectomized rats remains to be established (85, 
91). However, administration of estradiol decreases the turnover of NE 
in the POA and MBH of ovariectomized rats, concomitant with a reduction 
of circulating LH levels (105,106,110). Thus, disturbance of a stimu­
latory noradrenergic influence on LHRH release may produce estradiol's 
inhibitory effect on LH release. EPI appears to play little role in
regulating episodic LH release (92). Inhibition of EPI synthesis (92) 
or infusion of the catecholamine intraventricularly (88) were without 
effect on LH release suggesting that EPI is not involved in controlling 
pulsatile LH release.
3. Catecholamine Involvement in the Preovulatory or ovarian 
Hormone--Induced LH surge
Catecholamines were initially implicated in the regulation of LH 
release following observations that dibenamine, an adrenergic blocking 
agent, suppressed copulation--induced ovulation (93). Subsequent stud­
ies demonstrated that dibenamine and reserpine, depletors of monoamines 
from nerve terminals, blocked ovulation in normal cycling rats (94,95). 
Reserpine's inhibitory effect could be reversed by administering MAO 
inhibitors to prevent catecholamine metabolism (96).
Research over the last dozen years has solidified the involvement 
of catecholamines in the regulation of gonadotropin secretion and sug­
gested that NE is the primary mediator of ovarian hormone positive feed­
back effects. Interruption of NE synthesis with inhibitors of tyrosine 
hydroxylase or DBH inhibited preovulatory LH surges (97) and surges of 
LH induced by treatment of ovariectomized rats with estradiol and pro­
gesterone (98). The aforementioned inhibitory effects are reversed by 
injections of dihydoxyphenylserine (DOPS), a NE precursor (98). Preven­
tion of noradrenergic effects by receptor blockade with phenoxybenzamine 
or haloperidol also abolishes proestrus or ovarian hormone-induced LH 
surges (98,99). In addition, infusion of NE intraventricularly to pro-
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estrous rats or ovariectomized rats primed with ovarian hormones 
stimulates LH release (100,101) and NE is capable of promoting LHRH 
release both in vivo (102) and in vitro (103). More recently, ovarian 
hormone treatments that produce an LH surge have been shown to enhance 
the turnover of NE in the P0A and MBH of ovariectomized rats 
(104,103,106). Taken together, these findings provide support for the 
hypothesis that an increased noradrenergic neurotransmission underlies 
the stimulatory feedback effects of estradiol and progesterone on LHRH 
and LH release.
Whereas a stimulatory role for NE in gonadotropin secretion seems 
clear, the role of DA continues to be controversial. DA and the DA 
agonist apomorphine elevate LH concentrations when injected intraventri- 
cularly to cycling rats or ovarian hormone primed ovarectomized rats 
(102, 107) and elicits LHRH release from median eminence fragments in 
vitro (103). Moreover, DA turnover has been observed to be elevated on 
the afternoon of proestrus in the median eminence and arcuate nucleus 
(108). In contrast, DA and apomorphine reduce LH release in ovariecto­
mized rats (83,88) or do not affect LH release under a variety of endo­
crinological manipulations (88,100,1109). The inconsistency of effects 
found with DA has resulted in the failure to define a specific role, if 
any, for this catecholamine in the regulation of gonadotropin release, 
using the female rat as a model.
In contrast to NE, the role of central EPI systems in mediating
ovarian hormone feedback had been, until recently, overlooked. Although
EPI systems appear to play little role in episodic LH release (88,92),
several early reports revealed a possible stimulatory role in cycling 
animals. Intraventricular infusion of EPI elicits ovulation in estro­
gen-primed rabbits (111) and proestrus pentobarbital-treated rats 
(100). In addition, EPI stimulates LH release after intraventricular 
administration in ovariectomized rats primed with ovarian hormones (88, 
101). However, the low concentration of EPI compared to NE in the brain 
(112) and the non-specificity of drugs available to differentiate adre­
nergic effects from noradrenergic ones, prompted many investigators to 
discount the role of EPI in controlling LH secretion. In recent years, 
the development of specific PNMT inhibitors (113,114) provided a needed 
tool to define the involvement of EPI in ovarian hormone feedback.
Recent studies have demonstrated that selective inhibition of EPI 
synthesis prevents preovulatory (116) and ovarian hormone--induced LH 
surges (92,115). Thus, both NE and EPI may be involved in the stimula­
tory (positive) feedback effects of the ovarian hormones. A major goal 
of this research is to define the possible sites and mechanisms of 
action of the ovarian hormones on EPI systems and the relationship of 
these effects to ovarian hormone positive feedback.
4. Local Modulation of Catecholamine Activity
The mechanisms by which the ovarian hormones alter catecholamine 
activity to produce their stimulatory effects on gonadotropin secretion 
are not well understood. Although estradiol and progesterone may affect 
catecholamine systems directly, several lines of evidence suggest that 
the ovarian hormone— catecholamine interaction may be indirect (117).
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Estradiol and progesterone are taken up avidly in areas that receive 
ascending catecholaminergic innervation (38,614,118) and it is in these 
areas that the ovarian hormones seem to produce their effects on cate­
cholamine turnover and on LH release. In addition, the changes in 
catecholamine turnover produced by estradiol and progesterone are 
usually confined to a few discrete regions (108,110). These 
observations suggest that the ovarian hormones may effect the activity 
of intrahypothalamic systems that could exert discrete control over 
catecholamine release.
F. Role of Neuromodulatory Systems in Ovarian Hormone Feedback
1. The Endogenous Opioid Peptides--general considerations
The endogenous opioid peptides can be separated into three main 
groups: the enkephalins, peptides similar to beta-endorphin, and pep­
tides related to dynorphin (120). Different genes appear to code for 
the three groups of peptides. Pre--proopiomelanocortin (POMC) is an in­
active prohormone of which enzymatic cleavage produces several hormones 
including B--endophin, ACTH, and melanocyte stimulating hormone (121). 
Preproenkephalin is the 263 amino acid precursor for the enkephalin pep­
tides containing four copies of Met--enkephalin, one Leu--enkephalin 
peptide sequence, and two sequences of C-terminaily extended peptides, 
Met5— enkephalyl--Arg--Gly and Met5— enkephalyl--Arg--Phe (122,123).
Pre— prodynorphin containing 236 amino acids, is the precursor for 
dynorphin A, dynorphin B, and alpha--neo--endorphin (124).
The central distribution of the opioid peptides has only recently 
been revealed. The distribution of the enkephalins, presently the best
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characterized of the opioid peptides, includes cell bodies in the (1) 
telencephalon (caudate nucleus, nucleus accumbens, nucleus interstiti- 
alis of the stria terminalis (NIST), amygdala) with projections to, most 
importantly, the globus pallidus, but also to the amygdala and NIST; (2) 
the diencephalon, mainly the hypothalamus, with projections to areas 
including the median eminence, the supraoptic nucleus, and neurohypo­
physis; (3) the brain stem and spinal cord, with cell bodies and fibers 
in a variety of areas including substantial grisea centralis, inter­
peduncular nucleus, dorsal
tegmental nucleus, raphe area, nucleus of the solitary tract, dorsal 
horn and intermediolateral horn (125).
Cell bodies containing beta— endorphin appear to be concentrated 
almost exclusively in the arcuate nucleus of the MBH (126). Fibers 
originating from this area extend to the lateral septum and nucleus 
accumbens and are abundant in many nuclei of the hypothalamus (126). 
Other fibers project prominently to such brain stem sites as the peri­
aqueductal grey, the nucleus of the solitary tract, and the locus 
coeruleus (126).
The distribution of dynorphin and related peptides is less well 
established. Dynorphin A has been found in substantial amounts in the 
posterior pituitary (127) and seems to be concentrated in supraoptic and 
paraventricular nuclei (128) of the hypothalamus and the dorsal horn of 
the spinal cord (129).
The opioid peptides produce their biological effects through inter­
actions with a heterogenous population of receptors (130). The opioid
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receptors, termed mu, delta, sigma, kappa and epsilon, appear to bind 
different opiate and opioid peptides with varying degrees of specificity 
(131). Beta--endorphin seems to have equal affinity for mu and delta 
subtypes with little specificity for kappa receptors (131). The enke­
phalins, however, have much greater affinity for delta sites than mu, 
with little specificity for kappa sites. Recent evidence indicates that 
the dynorphin peptides may be the endogenous ligand for the kappa recep­
tor subtype (132).
2. Endogenous Opioid Peptides and Ovarian Hormone Positive 
Feedback
The endogenous opioid neuropeptides, such as the dynorphins, beta- 
endorphin, or met— enkephalin, are possibly involved in ovarian hormone 
feedback as neuromodulators of catecholamine activity for several 
reasons. First, neurons containing these peptides are located in estra­
diol target areas, including the POA and MBH (128,133,134). In fact, a 
recent study observed that beta— endorphin neurons in the arcuate nu­
cleus also accumulate estrogen (146) suggesting that these neurons are 
sites of estradiol action. The POA and MBH are also densely innervated 
by catecholamines (81,82). Secondly, the alkaloid opiate agonist, 
morphine, and the endogenous opioid neuropeptides reduce both central 
and peripheral NE release (135,136), most likely an action due to 
activation of inhibitory presynaptic receptors (137). Thirdly, morphine 
and the opioid peptides have profound neuroendocrine effects. Morphine 
and the opioid peptides depress the proestrous surge of LHRH and LH 
(138), block ovulation (139,140), and prevent in ovariectomized rats the
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surge of LH produced by treatment with ovarian hormones (141). In 
addition, the specific opioid receptor antagonist, naloxone, blocks 
these effects (138, HO, 14-1,142) and elevates LH when administered alone 
(HI , H 3 , 144,143). Moreover, morphine suppresses NE turnover enhanced 
by ovarian hormone priming (H). Recent pharmacological evidence sug­
gests that this effect of naloxone to increase LH release may be due to 
activation of the stimulatory NE and/or EPI systems (H1,H5). Thus, it 
is conceivable that ovarian hormones may alter the activity of an endo­
genous opioid neuropeptide system that regulates catecholaminergic 
neurotransmission. A second major focus of the present research will 
investigate the role of endogenous opioid peptides in modulating ovarian 
hormone effects on NE and EPI activity.
3. Gamma Aminobutyric Acid (GABA)--General Considerations
Gamma-aminobutyric acid (GABA) is the primary inhibitory neuro­
transmitter in the brain (H8). GABA acid is synthesized in the brain 
from glutamic acid catalyzed by the enzyme glutamic acid decarboxylase 
(GAD), with the coenzyme pyridoxal phosphate required (H8,H9). GABA 
Acid is further metabolized to succinic semialdehyde by the enzyme GABA: 
2— oxoglutamate aminotransferase (GABA— T), in a reaction also requiring 
pyrodoxal phosphate (H9). Succinic semialdehyde is converted to suc­
cinic acid by the enzyme succinic semialdehyde dehydrogenase.
GABA acid has been reported to have a specific distribution in mam­
malian brain (130,151,152). The distribution of GABA, determined by 
both biochemical and immunohistochemical methods, seems to be highest in 
hypothalamic (peri--and para ventricular, arcuate, preoptic, and
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anterior hypothalamic) nuclei, as well as the substantia nigra and glo­
bus pallidus (150,151,152).
Electrophysiological analysis of GABA effects has revealed two 
different mechanisms of actions (149). GABA receptor activation can 
lead to hyperpolarization of the target neuron, a result due to an 
enhanced chloride ion inhibition, GABA is also capable of 
pre--synaptically inhibiting nerve terminals by depolarization (149), an 
effect associated with an increased C1- ion conductance out of the 
neuron.
Results from biochemical, electrophysiological, and pharmacological 
studies have demonstrated the heterogeneity of central GABA receptors 
(154). Classical GABA A receptors appear to be linked to choride ion 
channels as stimulation of the GABA A receptor increases conductance 
leading to hyperpolarization (153). In contrast, GABA B receptors are 
not associated with chloride ion channels (154) but more possibly linked 
to voltage sensitive calcium channels in which activation depresses 
calcium conductance. GABA A and GABA B receptors may also be classified 
by pharmacological properties. Although GABA is a potent agonist at 
both sites, muscimol, isoguvacine, and Thip are active only at GABA A 
sites and inactive, or only weakly active at GABA B sites (154,158). 
Para--chloro--phenyl GABA (baclofen) is a potent agonist at GABA B 
sites and is inactive at GABA A receptors (159,160,161). GABA receptors 
also display differential sensitivity to antagonists. GABA A sites are 
antagonized by bicuculline (162) whereas GABA B receptors are insensi­
tive to bicuculline antagonism (159,160). Although a pure GABA B anta­
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gonist has not been identified, 5--aminovalerate may have some, albeit 
weak, GABA B antagonistic effects (163,164).
4. GABA and Ovarian Hormone Feedback
GABA is also a candidate for a neuromodulatory role in ovarian hor­
mone feedback. The reasons for suspecting GABA are very similar to ones 
for the endogenous opioid neuropeptides. GABA is densely concentrated 
in many hypothalamic regions, especially the medial basal area (150, 
151,152) were GABAergic fibers are mixed with monoaminergic and LHRH 
systems (165,166). Furthermore, GABA and GABA agonists, such as 
baclofen, reduce the evoked release of 3H--NE, both centrally and 
peripherally (159,163,167,168). However, the evidence is somewhat 
conflicting on the influence of GABA on LH release. For example, GABA 
stimulates LH release in anesthetized male rats (169) but is without 
effect in unanesthetized male rats (170). Intraventricular 
administration of GABA increases LH levels in ovariectomized and 
ovariectomized, ovarian hormone primed (171,172). However, more recent 
studies have been able to demonstrate an inhibitory influence of GABA 
and the GABA agonist, muscimol, on LH release (173,174,175). In these 
studies, intraventricular administration of GABA or muscimol reduces LH 
and suppresses POA NE turnover in ovariectomized or ovariectomized, 
ovarian hormone--primed female rats (173,174,175). Moreover, muscimol 
implanted locally into the POA decreases LH (175), and an estradiol 
treatment that reduced LH levels stimulated GABA turnover in the POA 
(174). Interestingly, a recent report noted that GABAergic neurons in 
the POA can accumulate delete estradiol (176) suggesting that estradiol
may affect GABA transmission in the PDA. Thus, it has been proposed 
that estradiol may produce its negative feedback effects by enhancing 
POA GABA turnover which would, in turn, suppress stimulatory 
noradrenergic inputs to LHRH neurons (173,174,175).
Other lines of evidence also support an ovarian hormone--GABA 
interaction. The activity enzyme mediating GABA synthesis, GAD, is 
increased to estradiol treatment (177,178) and intraventricular 
injection of GABA blocks ovulation in immature rats (179). Evidence 
presently available strongly suggests a role for GABAergic neurons in 
ovarian hormone negative feed-back. A third major portion of the 
present research will examine the role of GABAergic neurons in 




STATEMENT OF THE PROBLEM
This research tests the interrelated hypotheses that the ovarian 
hormones produce their positive feedback effects on LH secretion through 
activation of noradrenergic and adrenergic systems in specific hypotha­
lamic regions. Furthermore, the ovarian hormones may alter the activity 
of opioid neuropeptide and GABA systems to produce these alterations in 
catecholamine neurotransmission and gonadotropin secretion.
The specific objectives of these studies are to:
1) test whether selective catecholamine synthesis inhibitors pre­
vent the ovarian hormone--induced accumulation and decline of LHRH in 
the median eminence.
2) examine whether an ovarian hormone regimen that elicits an LH 
surge enhances the activity of NE and EPI neurons in discrete regions of 
the hypothalamus.
3) test whether the opiate antagonist, naloxone, enhances the 
activity of NE and EPI neurons in discrete regions of the hypothalamus.
4) test whether the opiate agonist, morphine, which blocks the LH 
surge, depresses the activity of NE and EPI neurons in discrete regions 
of the hypothalamus.
5) investigate the effects of the GABA A agonist, muscimol, the 
GABA B agonist, baclofen, and the GABA antagonist, bicuculline and 
5--aminovaleric acid on LH release.
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6) test whether the GABA agonists depress the activity of NE and 
EPI neurons in discrete regions of the hypothalamus.
7) test the effects of GABA agonists on the rise of LHRH induced 
by progesterone.
8)a) examine whether the GABA agonist, baclofen, reverses the 
enhancement of LH release and catecholamine activity produced by 
naloxone.
b) test whether the opiate antagonist, nalmefene, prevents the 
blockade of the LH surge produced by baclofen.
CHAPTER III
MATERIALS AND METHODS
A. Routine Animal Care
Adult, Sprague--Dawley albino female rats (Harlan Industries, Inc. 
Indianapolis) were used in the experiments, approximately 60 days of age 
at the beginning of each experiment. Animals were housed in groups of 
five and maintained on a 14 h light:10 h dark schedule (lights on 0500- 
-1900) with water and food ad libitum. All rats were ovariectomized and 
allowed two--three weeks recovery.
B. Brain Microdissection
The microdissection technique is based on that described by Palko- 
vits (180). After decapitation, brains are removed quickly and frozen 
on powdered dry ice. Three hundred micrometer thick coronal sections 
were cut at -4- degrees C on a microtome cryostat. Brain sections were 
frozen onto microscope slides. Individual brain nuclei were then re­
moved from the sections with stainless steel cannulae while viewed with 
a dissecting stereomicroscope. Generally, the appearance of brain ven­
tricles, tracts, and recognizable nuclei were relied upon to guide the 
dissection. The dissected tissue was placed into the appropriate medium 
(0.1 N HClOt* for catecholamines; 1 N HC1 for LHRH) and homogenized by 
sonication. Aliquots were removed for protein determination (181). The 
supernatent was then used for neurochemical analysis.
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C . Regional dissection o_f the hypothalamus
After decapitation, brains were removed rapidly and frozen on 
powdered dry ice. Two discrete brain regions were then dissected: 1) 
medial preoptic— anterior hypothalamic area (POA) and 2) medial basal 
hypothalamus (MBH). The POA fragment is bordered by the optic chiasm 
rostrally and supraoptic commissures caudally, the anterior commissure 
dorsally, and extendes approximately 1 mm lateral to the midline on 
either side. The MBH fragment was bounded by the rostral--caudal extent 
of the median eminence, the infundibular sulcus laterally, and extended 
approximately 1 mm dorsally. These areas were weighed, homogenized in 1 
ml of cold 0.1 N HClOt*, and centrifuged at 10,000 rpm for 30 minutes. 
Aliquots of sixty microliters were assayed for catecholamines with a 
sensitive radioenzymatic assay (182,183,184).
D. The alpha--Methyl Tyrosine Method
As an index of catecholaminergic activity, the studies measured the 
depletion of hypothalamic catecholamines one hour after administration 
of the catecholamine synthesis inhibitor alpha-methyl tyrosine (aMT).
The extent of catechoamine depletion after aMT administration depends 
largely upon the rate of nerve impulse flow (183). For example, after 
mid-thoracic spinal transection, the ability of aMT to reduce NE concen­
trations caudal to the transection is lost, suggesting that intact 
neuronal activity is essential for aMT to reduce NE levels (185). This 
method has since been used to study the effects of drugs on catechola­
mine function. A more pronounced decline after aMT indicates an
"increased release" of transmitterr from nerve terminals, while a 
smaller decline reflects a relatively low state of activity. The aMT 
method, like all non-steady state methods, carries the limitation that 
synthesis blockade, with subsequent increases in transmitter levels, may 
affect the normal activity of the system (186). Although the method is 
limited to a lesser extent in that it may not provide a true turnover 
rate per se (186), any differences between two groups in the degree of 
depletion reflect differences in turnover (185). Thus, this approach is 
most appropriate for comparing the effects of different experimental 
conditions on catecholamine function.
E. Analytical Methods
1. Catecholamines: Concentrations of catecholamines were deter­
mined by radioenzymatic assay (182,183). This assay used a partially 
purified preparation of catechol-O-methyltransferase to induce catecho­
lamine methylation with radiolabeled S-adenosyl-L-methionine acting as 
the methyl donor. The resulting methylated catecholamines were purified 
by solvent extraction and isolated by thin layer chromatography. The 
O-methylated compounds were then counted by liquid scintillation (18*0. 
The sensitivity of the assay is approximately equal to 5 pg for the 
three catecholamines.
2. Radioimmunoassay:
Luteinizing Hormone. In each study, trunk blood was collected 
after decapitation and centrifuged at 2000 rpm for 20 minutes. Serum 
was separated and stored at -85 degrees C. LH and prolactin were
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measured by double antibody radioimmunoassays, using NIADDK/NICHD Natio­
nal Hormone Pituitary Program reagents and procedures. Log logit data 
transformation was used for data calculation (178). The inter--and 
intraassay coefficients of variation for LH were 13.5% and 6%, respec­
tively.
LH--Releasing Hormone. LHRH was measured by the double antibody 
radioimmunoassay of Nett, et. al. (188), using the R— 4-2 antiserum. 
Synthetic LHRH (Peninsula Laboratories) was used for reference standard 
and for iodination. Monoiodinated LHRH was prepared by a modification 
of the chloramine T method (189). Intraassay coefficients of variation 
ranged from 1% to 7%, and the sensitivity of the assay was approximately 
0.5 pg/tube.
F . Hormone and Drug Treatments
Experiment 1: Effects of PNMT and DBH inhibitors on the LH and LHRH 
surges induced by ovarian hormones
In this study, as in other studies of the project that investigated 
the positive feedback effects of the ovarian hormones, stimulatory 
sequential ovarian hormone priming was used. In each study, ovariecto- 
mized female rats received sc injections of estradiol benzoate (EB; 50 
micrograms at 1000 h) followed by progesterone (P; 2.5 mg) 48 h later. 
Henceforth this shall be simply referred to as EB— P priming.
In each study of experiment 1, the animals received the EB--P prim­
ing. Beginning 1 h before the progesterone injections, animals received
ip injections of one of the following 1) the EPI synthesis inhibitor
SKF 64139 (30 mg/kg), 2) the DBH inhibitor FLA-63 (40 mg/kg), or 3) 
the EPI synthesis inhibitor LY 78335 (50 mg/kg). The EPI synthesis 
inhibitors were dissolved in saline while FLA-63 was dissolved in 1 N 
HC1, buffered to pH 6.8 and diluted in saline. In each experiment, 
appropriate saline vehicle controls were conducted simultaneously. 
Selected animals were killed by decapitation at various times after 
progesterone treatment in order to encompass the changes in tissue LHRH 
and plasma LH concentrations. Plasma LH and median eminence LHRH were 
measured by radioimmunoassay. To varify the effectiveness of the 
catecholamine synthesis inhibitors, concentrations of NE, EPI, and DA 
were determined in the POA.
Experiment 2: Effects of ovarian hormones on catecholamine activity in 
the hypothalamus.
This study tested whether hypothalamic catecholamine neurons are 
activated by an ovarian hormone treatment that induces an LH surge. 
Ovariectomized rats received sequential oil or EB-P priming and were 
sacrificed either 3h after progesterone (or oil) or 6h after proges­
terone treatment. The period 3 h after progesterone corresponds to the 
approximate time during which LHRH levels are increased in the median 
eminence. The period 6 h after progesterone corresponds to the time of 
the LH surge. One hour before decapitation, half of the animals in each 
group were given ip injections of saline, and half received the catecho­
lamine synthesis inhibitor alpha-methyl tyrosine methyl ester HC1 (400 
mg/kg base; aMT). Concentrations of NE, EPI, and DA in the POA and MBH
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were determined by radioenzymatic assay.
Experiment 3: Effects of naloxone on LH release and catecholamine turn­
over in the POA and MBH of estradiol— primed rats.
This experiment was designed to test whether naloxone, an opiate 
antagonist, mimics the effects of progesterone in increasing LH release 
and catecholamine turnover in rats primed with estradiol. In this 
experiment, rats were primed with EB at 1000h. Fifty hours later 
(1200h), animals received ip injections of either saline vehicle or 
naloxone HC1 (10 mg/kg) and were sacrificed 1 h later. In order to 
assess catecholamine activity, one half of the animals in each group 
were given aMT (400 mg/kg) simultaneously with the naloxone or saline. 
Plasma LH was determined by radioimmunoassay and catecholamine 
concentrations in POA and MBH were measured with radioenzymatic assay.
Experiment 4: Effects of morphine on LH release and on catecholamine 
turnover in the POA and MBH of EB-P primed rats.
This experiment tested whether the opiate agonist, morphine which 
blocks the LH surge, will also prevent the stimulation of catecholamine 
turnover induced by estradiol and progesterone. Animals received the 
EB-P priming and were sacrificed 3 h later. One hour prior to decapita­
tion, groups of progesterone treated animals received either saline, 
morphine HC1 (10 mg/kg), or morphine plus naloxone HC1 (3 mg/kg). At 
the same time, half of the animals in each group received aMT. Doseages 
of opiate drugs used in Experiments 3 and 4 were chosen on the basis of 
those doses known to affect LH release. Plasma LH was determined by
radioimmunoassay and catecholamine concentrationsin POA and MBH were 
measured with a radioenzymatic assay.
Experiment 3: Effects of GABA agonists and antagonists on LH secretion 
in ovariectomized and ovariectomlzed, ovarian hormone-primed rats.
The first study of Experiment 5 was designed to test the effects of 
GABA agonists and antagonists on the surge of LH induced by the ovarian 
hormones. Animals received seguential oil or EB-P injections. Concomi­
tant with the progesterone injections, animals were given ip injections 
of either saline vehicle, the barbiturate, phenobarbital (50 mg/kg), the 
selective GABA B agonist, baclofen (10 mg/kg), or the GABA A agonist, 
muscimol (2 mg/kg). Additional animals in each group also received the 
postsynaptic GABA A antagonist, bicuculline (1 mg/kg) or the putative 
GABA B antagonist, 5 aminovaleric acid (10-150 mg/kg), simultaneously.
In order to ensure maximal duration of drug action, half of the animals 
in each group received a second injection at 14-00 h of their respective 
agonist or agonist plus antagonist.
A second study tested whether the GABA agonists, baclofen or musci­
mol, directly affect the anterior pituitary gland. Rats were given the 
stimulatory EB-P priming. Beginning with the progesterone injections, 
the animals received simultaneous ip injections of either saline vehi­
cle, baclofen (10 mg/kg), or muscimol (2 mg/kg). Two hours after pro­
gesterone (1200 h), animals received either saline vehicle or 100 ng 
synthetic LHRH subcutaneously and were sacrificed 15 minutes later.
A third study was performed to examine the effects of the GABA ago­
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nists on LH release In ovariectomized, hormonally untreated rats. In 
this experiment, ovariectomized rats received at 1200 h ip injections of 
either saline vehicle, baclofen (10 or 20 mg/kg), or muscimol (2 mg/ 
kg). Additional agonist treated animals were also given bicuculline 
(1-4 mg/kg) simultaneously. Animals were sacrificed by decapitation one 
hour after drug treatment. LH was determined by radioimmunoassay.
Experiment 6: Effects of GABA agonists on catecholamine turnover in the 
POA and MBH of rats treated with ovarian hormones.
Experiment 6 was designed to test whether GABA agonists alter hypo­
thalamic catecholamine activity in rats pretreated with ovarian hormo­
nes. In this study, ovariectomized rats received the stimulatory EB-P 
priming, and were sacrificed 3 h after progesterone. Concomitant with 
the progesterone injections, animals received ip injections of either 
baclofen (10 mg/kg), muscimol (2 mg/kg), or saline vehicle. To assess 
effects on catecholamine activity, one hour before decapitation, half of 
the animals in each group received aMT (400 mg/kg). Plasma LH was 
determined by radioimmunoassay and catecholamine concentrations in POA 
and MBH were measured with a radioenzymatic assay.
Experiment 7; Effects of <i GABA agonists on the median eminence 
accumulation of LHRH induced by progesterone.
This study was designed to test whether the GABAg agonist, baclo­
fen, can prevent the ovarian hormone stimulation of LHRH concentrations 
in the median eminence. Animals received the stimulatory EB-P priming.
Concomitantly with the progesterone injections, animals received ip 
injections of either baclofen (10 mg/kg), or saline vehicle. Animals 
were sacrificed either 1, 2, 3, 4, or 6 hours after progesterone in 
order to encompass the changes in tissue LHRH and plasma LH concentra­
tions. Animals sacrificed 6 h after progesterone received a second 
injection of their respective drug or saline treatment at 14-00 h. LHRH 
and LH were measured by radioimmunoassay.
Experiment 8at Effects of baclofen on naloxone's enhancement of LH 
release and catecholamine activity in estradiol-primed rats.
Experiment 8b: Effects of nalmefene on the blockade of the LH surge 
produced by baclofen.
Two studies examined the interactions between GABA agonists and 
opiate antagonists and their relationship to LH release and catechola­
mine activity.
In the first study, ovariectomized rats received sc injections of 
EB followed fifty hours later (1200 h) by ip injections of either saline 
vehicle or naloxone HC1 (10 mg/kg). Simultaneously, one half of the 
animals in each group received saline or aMT and were sacrificed one 
hour later. In order to assess the effects of baclofen on naloxone- 
induced catecholamine turnover, 30 minutes before naloxone, EB primed 
animals were given either baclofen or saline.
A second experiment was designed to test whether the opiate anta­
gonist, nalmefene, prevents the blockade of the EB-P priming effect. At
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the time of the progesterone administration, animals received ip 
injections of either saline, baclofen (10 mg/kg), nalmefene (10 mg/kg), 
or baclofenplus nalmefene. To assure maximal duration of drug action, 
all animals received at 1400 h a second injection of their respective 
drug or drug plus antagonist treatment. All animals were sacrificed 6 h 
after progesterone (1600 h). LH was measured by radioimmunoassay and 
catecholamine concentrations in the MBH were determined with a 
radioenzymatic assay.
G. Statistical Analysis
Single factor or two-factor analysis of variance and Newman--Keuls 
tests were applied to determine levels of significance in changes in LH 





Experiment 1: Effects of PNMT and DBH inhibitors on LH and LHRH surges 
induced by ovarian hormones.
As depicted in Figs. 1 and 2, the administration of progesterone at 
1000 h to estrogen-pretreated rats significantly increased LHRH concen­
trations in the median eminence at 1300 h. This elevation was followed 
by a significant decline at 14-00 h, and the levels did not change signi­
ficantly thereafter. As reported previously (190), peak LHRH concentra­
tions occurred before the highest levels of LH. Pretreatment with the 
catecholamine synthesis inhibitors blocked or delayed the LH surge, but 
had differential effects on the changes in median eminence LHRH. Figure 
1 shows that the EPI synthesis inhibitor SKF 64-139 partially blocked the 
rise of LHRH seen at 1300 h. In these animals, LHRH concentrations 
increased significantly, but the magnitude of the effect was signifi­
cantly less than that in the controls. LHRH concentrations were similar 
in the two groups at 14D0 and 1600 h.
In a second experiment, the highest levels of LH were observed in 
the controls at 14-00 h. Pretreatment with LY 78335, another EPI 
synthesis inhibitor, appeared to delay the LH surge by 2h, at which time 
LH concentrations were significantly higher than controls. LY 78335- 




Pretreatment with FLA-63, which inhibits both NE and EPI synthesis, 
also abolished the ovarian hormone-induced LH surge, but in contrast to 
the effects of SKF 64-139, completely prevented the rise of LHRH in the 
median eminence (Table 1). In this study, control animals showed signi­
ficant increases in median eminence LHRH levels at 1400 and 1630 h com­
pared to 1300 h valves. However, after treatment with FLA-63, LHRH 
levels failed to increase and progressively decreased from 1300 to 1630 
h.
Thus, the LH surge can be prevented by inhibiting to synthesis of 
NE or EPI but the synthesis of both NE and EPI must be prevented to 
block the increase in LHRH concentrations in the ME.
37
TIME
Figure 1. Effects of SKF 64139 on plasma LH and median eminence LHRH 
concentrations, d, Time of drug administration; p, time of progesterone 
administration. *P<0.05; **P<0.01 (vs. saline-treated controls, based











Figure 2. Effects of LY78335 on plasma LH and median eminence LHRH 
concentrations. Timing of injections is described in Fig. 1. *, P<
0.05, **, P< 0.01 (vs. saline-treated controls, based on analyses of 
variance and Newman-Keuls tests).
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TABLE I
EFFECTS OF FLA-63 ON THE CONCENTRATIONS OF LH IN PLASMA (A) AND 




A. LH (ng/ml) 
Saline 465±32 422±47 970±230**
FLA-63 336±28 381±23 382 ±50
B. LHRH (pg/micg) 
Saline 14.4-±1.9 22.4±2.6** 26.6±3.0**
FLA-63 17.4-±1.5 16.4±1.4 9.6±2.0***
Values are the mean ± SEM (n=10).
*P<p.01 vs. ail others, based on analysis of variance and Newman-Keuis 
tests.
**P<0.01 vs. saline-treated group at 1300 h
***P<0.01 vs. saline treated group at 1630; P<0.05 vs. FLA 1300-treated 
group.
Table 2 illustrates the effectiveness of the catecholamine synthe­
sis inhibitors In reducing NE and/or EPI concentrations in the medial 
preoptic nucleus. The DBH inhibitor FLA-63 significantly decreased both 
NE and EPI concentrations and significantly increased DA levels. Both 
SKF 64-139 and LY 78334- decreased preoptic levels of EPI but had no
effect on NE or DA.
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TABLE II
EFFECTS OF SKF 64139, LY 78335, AND FLA-63 ON 




Saline FLA-63 SKF 64139 LY 78335
NE 30.2±1.7 8.8±1.2* 25±1.6 30.5±1.7
EPI 0.48±0.04 0.22±0.04 0.28±0.03 0.33±0.02*
DA 1.6±0.2 6.5±0.6* 1.2±0.09 1.7±0.1
Values are the mean ± SEM, expressed as picograms per microgram protein 
(n = 25-26).
*P<0.01 based on analyses of variance and Newman-Keuls tests.
Experiment 2: Effects of ovarian hormones oji catecholamine activity in 
the hypothalamus.
Results from this study revealed that the estrogen plus 
progesterone treatment that produces an LH surge, differentially 
affected the steady state concentrations and extent of depletion of NE 
and EPI in the POA and MBH. As shown in Fig. 3, the aMT-induced decline 
of EPI was significantly enhanced at 1300 h and at 1600 h in the MBH 
after progesterone treatment. There were no significant decreases in 
EPI in the POA after aMT administration in rats treated with oil, or 






























Figure 3. Effects of estradiol plus progesterone (E 
the depletion of EPI in the MPO-AH and MBH after aMT 
(MPO-AH), PC0.05 vs. oil-saline (SAL)-treated group; 
vs. saline-treated group.
+ P) treatment on 
treatment. *,
*, (MBH), P<0.05
but significant, decreases in steady state EPI concentrations in the 
POA.
Estradiol plus progesterone increased the magnitude of the 
aMT-induced depletion of NE in both hypothalamic regions at 1300 h 
(Fig. 4). The turnover of NE was reduced to the oil vehicle levels at 
1600 h in these areas. Figure 4 also shows that basal, steady state 
concentrations of NE were significantly decreased by the ovarian 
hormones.
The levels and aMT-induced decline of DA were not affected in 




Figure 4. Effects of estradiol plus progesterone (E + P) treatment on 
the depletion of NE in the MPO-AH and MBH after aMT treatment. *, 
P<0.05 vs. oil-saline (SAL)-treated group; **P<0.01 vs. saline-treated 
group.
TABLE III
EFFECTS OF ESTRADIOL BENZOATE AND PROGESTERONE (EB & P) 
ON THE LOCALIZED DEPLETION OF DA INDUCED BY aMT 
IN THE POA AND MBH
Treatment
POA MBH
Saline aMT Saline aMT
Oil 317±53 172±36 637±45 436±21
**EB & P, 1300 h 24-1 ±22 165±20 560±23 363±30
**EB & P, 1600 h 306±37 170±28* 526±35 385±25*
Values are the mean ± SEM, expressed as picograms per mg (n = 9-10). 
*P<0.05 vs. saline-treated group, based on analyses of variance and 
Newman-Keuls tests.
*P<0.01 vs. saline-treated group, based on analyses of variance and 
Newman-Keuls tests.
Experiment 3: Effects o_f naioxone on LH release and catecholamine 
turnover in the POA and MBH of estradiol-primed rats.
Naloxone administration to EB-pretreated rats significantly 
increased circulating LH concentrations one hour later, as compared to 
saline controls (Table 4).
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TABLE IV
EFFECT OF NALOXONE ON 
HORMONE
LH CONCENTRATIONS IN OVARIAN 
-TREATED RATS
Group LH, ng/ml
EB + saline 335±52
EB + naloxone 608±43*
Values are expressed as ng/ml serum ± SEM in this and 
subsequent Tables and Figures.
*P<0.01, t test 
n=8-10
Figures 5 and 6 present the effects of naloxone on the aMT-induced 
decline of NE and EPI, respectively, in the two diencephalic regions.
In the EB-saline controls, there were no significant declines in either 
catecholamine levels 1 h after aMT, suggesting a low level of activity 
in these regions.
However, the administration of aMT significantly increased the 
depletion of NE in both the POA and MBH and also increased the decline 
of EPI in the MBH of EB-naloxone treated rats, suggesting increased 
catecholamine activity. Naloxone did not alter the effects of aMT on 
EPI or DA depletion in the POA (figs. 2, 3), but produced a small, 
significant enhancement of DA depletion in the MBH (fig. 7).
Experiment 4: Effects of morphine on LH release and catecholamine 
turnover in the POA and MBH of EB-progesterone treated rats.
Table 5 shows that morphine decresed LH levels in EB-P treated *
rats.
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Figure 5. Effects of naloxone (NAL) or saline (SAL) on the depletion of 
NE after aMT in estradiol-primed rats. Statistical analysis (based on 
2-factor analysis of variance and Newman-Keuls tests). MBH: *P<0.05 
vs. respective saline, P<0.05 vs. EB and SAL-aMT. POA-AH: *P<0.01 vs. 




Figure 6. Effects of naloxone on the depletion of EPI after ccMT.
Abbreviation, coding and statistical analysis as in figure 5. *P<0.
vs. respective saline and vs. EB and SAL-ctMT.
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MBH
Figure 7. Effects of naloxone on the depletion of DA after aMT 
Abbreviations, coding and statistical analysis as in figure 5. MBH: **P 
0.01 vs. respective saline; *P<0.01 vs. respective saline and PC0.05 
vs. EB and SAL-aMT. POA-aMT. POA-AH: **P<0.01 vs. respective saline.
TABLE V
EFFECTS OF MORPHINE AND MORPHINE PLUS NALOXONE ON LH 
CONCENTRATIONS IN OVARIAN HORMONE-TREATED 
FEMALE RATS
Group LH, ng/ml + SEM
EB + progesterone + saline 309±84**
EB + progesterone + morphine 123±34
EB + progesterone + morphine + naloxone 343±62* *
**P<0.01 vs. EB + progesterone + morphine, based on analysis of variance 
and Newman-Keuls tests.
The catecholamine synthesis inhibitor, a-MT, produced significant 
depletions of NE in the POA and MBH (fig. 8) and of EPI in the MBH 
(fig. 9) in controls treated with estradiol and progesterone. Figures 8 
and 9 show that administration of morphine to such animals reduced NE 
and EPI depletion by aMT in these areas, and also diminished the 
decrease in MBH DA after aMT, suggesting decreased catecholamine turn­
over in these regions.
Steady-state concentrations of catecholamines were not altered by 
morphine with the exception of NE in the POA. In this region, mor­
phine-treated rats showed significantly decreased NE concentrations com­
pared to the progesterone-saline group. NE levels were not decreased 
further by aMT. Addition of naloxone at least partially antagonized
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PROG PROG & PROG,
MOR MOR & NAL
Figure 6. Effects of morphine (MOR) and naloxone (NAL) on the depletion 
of NE after aMT in animals pretreated with estradiol plus progesterone 
(PROG). Statistical analysis as in figure 5. MBH: ***P<0.01 vs. 
respective saline; **P<0.01 vs. PROG-aMT; *P 0.01 vs. respective saline, 
*P 0.05 vs. respective saline.
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MOR MOR&NAL
Fig. 9. Effects of morphine and naloxone on the depletion of EPI and DA 
in the MBH. Abbreviations, coding, and statistical analysis as in 
figjre 5. EPI results: *P<0.05 vs. respective saline; D*\ results: 
**P<0.01 vs. respective saline; *P<0.05 vs. PROG-aMT and PROG, MOR and
NAL-aMT.
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these inhibitory effects of morphine. Neither progesterone nor the 
opiate drugs altered EPI or DA depletion in the POA.
Experiment 5: Effects of GABA agonists and antagonists on LH secretion 
in ovariectomized and ovariectomized, ovarian hormone-primed rats.
As presented in Table 6, administration of progesterone at 1000 h 
to EB-primed rats markedly stimulated serum LH concentrations.
Treatment of steroid-primed rats at 1000 h and 1400 h with either 
baclofen or muscimol prevented the rise in serum LH levels. The GABA A 
antagonist, bicuculline, failed to antagonize the inhibitory effects of 
baclofen but reduced the effect pf muscimol on LH release. The putative 
GABA B antagonist, 5-aminovalerate, failed to antagonize baclofen's 
inhibitory effect on the LH surge (Table 7). A single injection of 
baclofen given with progesterone, also significantly reduced, but did 
not totally prevent, the LH surge produced by the ovarian hormone 
regimen, while a single injection of muscimol was less effective.
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EFFECTS OF BACLOFEN AND MUSCIMOL ON THE EB PLUS 
P-INDUCED LH SURGE
TABLE VI
Hormone Treatment LH (ng/ml) n
Oil and saline 400±27** 24
EB + P + Saline 2202±273 25
EB + P + Baclofen
(10 mg/kg x 1) 1163 ±229** 10
(10 mg/kg X 2) 129±28** 13
+ bicuculline* 250±28** 7
EB and P and muscimol
(2 mg/kg x 1) 1673±98 8
(2 mg/kg x 2) 145±14** 14
+ bicuculline# 808±170** 12
Ovariectomized rats received EB followed 4-8 h later by P (injections at 
1000 h). Drug injections were given at 1000 h (x1 or at 1000 h (x2). 
♦Baclofen (10 mg/kg) plus bicuculline (1 mg/kg) at 1000 h and 1400 h. 
#Muscimol (2 mg/kg) plus bicuculline (1 mg/kg) at 1000 h and 1400 h. 
**P<0.01 vs. EB + P+ Saline. *P<0.05 vs. EB + P + Muscimol x 2.
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EFFECTS OF 5-AMINOVALERATE (5AV) ON BACLOFEN'S 
BLOCKADE OF THE LH SURGE
TABLE VII
Treatment LH (ng/ml)
EB + Progesterone (Prog.) 2373±873
EB + Prog. + baclofen (10 mg/kg) 207±25*
EB + Prog. + baclofen + 5AV (10 mg/kg) 286±102*
EB + Prog. + baclofen + 5AV (25 mg/kg) 103±13*
EB + Prog. + baclofen + 5AV (50 mg/kg) 127±24-*
EB + Prog. + baclofen + 5AV (75 mg/kg) 530±230*
EB + Prog. + baclofen + 5AV (125 mg/kg) 154-±31*
EB + Prog. + baclofen + 5AV (150 mg/kg) 130±23*
*P<0.01 vs. EB + Prog. 
n=5-7
Table 8 shows that phenobarbltal administration to rats primed with 
the ovarian hormones blocks the LH surge. Concurrent injections of 
bicuculline with phenobarbital, and by itself at 1400 h, failed to 
reverse the barbiturate's effect.
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EFFECTS OF BICUCULLINE AND 5-AMINOVALERATE ON (5AV)
TABLE VIII
PHENOBARBITAL'S BLOCKADE OF LH SURGE
Treatment LH (ng/ml)
EB + Progesterone 3799±1280
EB + Prog. + Phenobarbital (Pb) (50 mg/kg) 223±21*
EB + Prog. + Pb + bicuculline (2 mg/kg) 177±22*
EB + Prog. + Pb + bicuculline (4 mg/kg) 182±18*
EB + Prog. + Pb + 5AV (75 mg/kg) 205±39*
EB + Prog. + Pb + 5AV (150 mg/kg) m ± 6 *
*P<0.01 vs. EB + Prog 
n=5-7
Table 9 shows that a 100 mg dose of synthetic LHRH produced a 
dramatic rise in plasma LH concentrations within 15 minutes. 
Administration of baclofen and muscimol, in doses that blocked the 
progesterone-induced rise of LH, failed to affect this increase.
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EFFECTS OF BACLOFEN AND MUSCIMOL ON LH RELEASE INDUCED 
BY ADMINISTRATION OF LHRH
TABLE IX
Treatment LH (ng/ml)
EB + Progesterone (Prog.) + Saline 377±16
EB + Prog. + LHRH 3342±332**
EB + Prog. + LHRH + Baclofen 3378±538**
EB + Prog. + LHRH + Muscimol 3967±372**
**P<0.01 vs. EB + P + saline 
n=5-7
In a third study, baclofen and muscimol, in doses that blocked the 
LH surge, did not significantly depress basal LH release in ovari- 
ectomized, hormonally untreated rats (Table 10). A two-fold higher dose 
of baclofen tended to depress LH levels, but the effect did not quite 
reach statistical significance. Bicuculline did not block and tended to 
somewhat enhance baclofen's suppression of basal LH release.
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Muscimol (2 mg/kg) 501+76
Muscimol (2 mg/kg)
and bicuculllne (1 mg/kg) 435+31
Baclofen (10 mg/kg) 531+65
Baclofen (10 mg/kg)
and bicuculllne (1 mg/kg) 507+33
Baclofen (20 mg/kg) 443+54
Baclofen (20 mg/kg)
and bicuculllne (2 mg/kg) 390+46*
Baclofen (20 mg/kg)
and bicuculline (4 mg/kg) 312+46**
*P<0.05, **P<0.01 vs. saline 
n=5-8
Experiment 6: Effects o_f GABA agonists on catecholamine turnover in the 
POA and MBH of rats treated with ovarian hormones.
The synthesis inhibitor, aMT, produced significant depletion of NE, 
EPI, and DA in the MBH (Fig. 10, 11, 12) and of NE in the POA (Fig. 10) 
in control animals treated with EB followed by progesterone. Admini­
stration of baclofen or muscimol significantly decreased steady state 
concentrations of NE and EPI in these regions. In addition, aMT did not 















Figure 10. Effects of baclofen and muscimol on the depletion of
norepinephrine (NE) produced by aMT in the POA-AH and MBH.







Figure 11. Effects of baclofen and muscimol on the depletion of
epinephrine (EPI) produced by aMT in the POA-AH and MBH.




Figure 12. Effects of baclofen and muscimol on the depletion of dopa­
mine (DA) produced by aMT in the POA-AH and MBH. **P<0.01 vs. respec­
tive SAL.
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(Fig. 10 & 11), suggesting decreased catecholaminergic activity in these 
areas. These drugs did not alter the concentrations or depletion of DA 
in either the MBH or POA (Fig. 12).
Experiment 7: Effects o_f the GABAr agonist baclofen on the median 
eminence accumulation of LHRH induced by progesterone.
As illustrated in Table 11, administration of progesterone at 1000 
h to estradiol-primed animals significantly elevated plasma LH levels at 
1400 h and 1600 h. Treatment of ovarian hormone-primed rats with the 




EFFECTS OF BACLOFEN ON THE PROGESTERONE-INDUCED RISE 




1100 h 222±26 190±40
1200 h 187±39 227±54
1300 h 240±62 113 ±19
U00 h 938±62** 208±55*
1600 h 2873±599** 72 ±8*
**P<0.01 vs. 1100, 1200, and 1300 h saline values 
*P<0.01 vs. respective saline 
n=7-9
Administration of progesterone at 1000 h to estradiol treated rats, 
produced significant elevations in median eminence LHRH concentrations 
at 1100 h. LHRH concentrations declined significantly at 1200 h and 
1300 h. In rats pretreated with baclofen, the ovarian hormone priming 
again resulted in an increase in LHRH levels at 1100 h but levels did 
not change significantly thereafter. In fact, concentrations of LHRH 
were significantly higher at 1400 h.
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TABLE XII
EFFECTS OF BACLOVEN ON THE PROGESTERONE-INDUCED ACCUMULATION 
IN LHRH CONCENTRATIONS IN THE MEDIAN EMINENCE OF 
ESTRADIOL-PRIMED RATS
LHRH (pg/microgram protein - ME)
Time Saline Baclofen
1000 h 29 ±2
1100 h 4-2 ±3* 4-9 ±5
1200 h 38 ±5 34-±9
1300 h 30±3** 35 ±5
14-00 h 21±3** 37+6***
1600 h 28 ±2 33 ±5
*P<0.01 vs. 1000 h saline control
**P<0.01 vs. 1100 h saline control
**P<0.05 vs. respective saline control 
n=7-9
Experiment 8a: Effects of baclofen oji naloxone's enhancement of LH 
release and catecholamine activity in estradiol-promed rats.
In the first study of Experiment 8, administration of naloxone to 
estradiol-primed rats significantly elevated serum LH levels (Table 
13). Pretreatment, 30 minutes before naloxone, with baclofen failed to 
affect the increase in LH release elicited by naloxone.
TABLE XIII
EFFECTS OF BACLOFEN ON NALOXONE'S ENHANCEMENT OF LH RELEASE
Treatment LH (ng/ml)
EB + Saline 123±12
EB + Naloxone (10 mg/kg) + Saline 277±32**
EB + Naloxone + Baclofen (10 mg/kg) 223±35*
** p<0.01 vs. EB + Saline control 
* p<0.05 vs. EB + Saline control 
n=7-8
Tables 14-16 present the effects of naloxone on catecholamine 
depletion induced by aMT in the MBH. In the EB-saline controls, there 
was no significant decline in either NE or EPI after aMT, suggesting a 
low level of activity in these areas (Table 14 and 15). However, admin­
istration of naloxone significantly potentiated the depletion of NE and 
EPI in the MBH, suggesting increased catecholamine turnover (Table 14 
and 15). Pretreatment with baclofen failed to prevent naloxone's 




EFFECTS OF BACLOFEN ON NALOXONE'S ENHANCEMENT OF NE DEPLETION 
INDUCED BY aMT IN THE MBH OF ESTRADIOL-PRIMED RATS
pg NE/mg tissue
Treatment Saline aMT
EB + Saline 776±155 481±111
EB + Naloxone 1408±187* 758±113**
EB + Naloxone + Baclofen 1141±112* 628±77**
*P<0.05 vs. EB saline
**P<0.05 vs. respective saline 
n=7-8
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EFFECTS OF BACLOFEN ON NALOXONE'S ENHANCEMENT OF 







EB + Saline 19±5 13±2
EB + Naloxone 40±5* 26 ±5*
EB + Naloxone 29 ±3 20±3**
*P<0.05 vs. EB saline
**P<0.05 vs. respective saline 
n=7-8
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EFFECTS OF BACLOFEN ON NALOXONE'S ENHANCEMENT 




EB + Saline 340±48 163±42**
EB + Naloxone 475±70* 205±21**
EB + Naloxone + Baclofen 650±43* 168±22**
*P<0.05 vs. EB saline 
**P<0.05 vs. respective saline 
n=7-8
Experiment 8b; Effects of nalmefene on the blockade of the LH surge 
produced by baclofen.
The results from the second study in Experiment 8 are illustrated 
in Table 17. Administration of progesterone at 1000 h to estradiol 
primed rats elicited a significant elevation of serum LH concentra­
tions. Pretreatment of ovarian hormone-primed rats at 1000 h and 1400 h 
with baclofen significantly attenuated the LH surge. Pretreatment with 
nalmefene at 1000 and 1400 h did not significantly alter LH concentra­
tions. The concomitant administration of nalmefene with baclofen did 
not prevent baclofen's inhibitory effect on the ovarian hormone-induced 
surge of LH.
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EFFECTS OF NALMEFENE ON BACLOFEN'S BLOCKADE 
OF THE LH SURGE
TABLE XVII
Treatment LH (ng/ml)
EB + Progesterone (Prog.)
EB + Prog. + Baclofen (10 mg/kg) 
EB + Prog. + Nalmefene (10 mg/kg) 









Experiments 1 and 2 were designed to define more completely the 
role of the catecholamines, especially EPI in mediating the stimulatory 
or positive feedback effects of the ovarian hormones on LHRH and LH 
secretion. Results from these studies suggest that both NE and EPI sys­
tems are involved in the effects of estrogen and progesterone in stimu­
lating the accumulation of LHRH in the median eminance and the release 
of LH from the anterior pituitary.
Inhibition of both NE and EPI synthesis with the DBH inhibitor, 
FLA-63, completely prevented the LH surge and accumulation of LHRH in 
the median eminence that occur in the afternoon after progesterone 
treatment. These results are consistent with earlier work in which 
administration of another DBH inhibitor, diethyldithiocarbamate, pro­
duced similar effects on median eminence LHRH concentrations and pitui­
tary LH release (190). While these earlier results were attributed to 
blockade of NE synthesis, the present studies indicate that a portion of 
the inhibitory effect may be due to interference with EPI neurotransmis­
sion. Administration of the selective EPI synthesis inhibitor, SKF 
64-139, partially blocked the progesterone-induced afternoon increase in 
median eminence LHRH concentrations and prevented the LH surge. Thus, 
while depletions of both NE and EPI completely prevented the increase in 
LHRH concentrations, selective depletion of EPI resulted in an increase 
that was significantly smaller in magnitude than the control LHRH 
value. These findings indicate that both NE and EPI systems are acti­
vated to produce the full accumulation of LHRH, and that under condi­
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tions of reduced EPI neurotransmission, the smaller rise in LHRH concen­
trations reveals that there is also a contribution of that neurotrans­
mitter system.
The results obtained with the second EPI synthesis inhibitor, LV 
78335, also support the conclusion that EPI neurons are involved in ova­
rian hormone effects on LHRH and LH release. Administration of LY 78335 
interfered with progesterone effect to increase the accumulation of LHRH 
in the median eminence and the pituitary release of LH, that is, the 
increases in LHRH and LH release were delayed compared with those in the 
concurrently run controls. Indeed, rats treated with LY 78335 may have 
shown a rebound phenomenon as levels of LHRH and LH were significantly 
greater at 1600 h then the corresponding control values. The two EPI 
synthesis inhibitors exhibited different patterns of effects on LHRH. 
This may reflect a shorter duration of neuroendocrine action for LY 
78335 than SKF 64139, as suggested previously by the effects of these 
two drugs on GH secretion (191). However, it is evident from the 
results of these studies that inhibition of EPI synthesis interferes 
with the ovarian hormone stimulatory effects on LH and LHRH.
Despite a significant increase in median eminence LHRH concentra­
tions, the administration of SKF 64139 totally prevented the subsequent 
surge of LH induced by the ovarian hormones. These effects of SKF 64139 
are similar to those produced by the barbiturates which also block the 
LH surge (192) but fail to prevent the increase in LHRH that precedes 
the preovulatory or ovarian hormone induced LH surge (193,194). The 
significance of the sequential LHRH increase and decrease that occurs
several hours after progesterone treatment is unclear. Others have 
proposed that the rise of LHRH may represent increased synthesis 
(190,193), while a more recent report observed decreased degradation of 
LHRH by an endopeptldase at this time (195). The results of this and 
other studies (190) suggest that the elevation of LHRH In the median 
eminence is dependent upon catecholamine neurotransmission and appears 
to be necessary, but not sufficient, for the subsequent LH surge. 
However, the physiological significance of the decline in LHRH levels 
that follows the elevation is not clear. It is probable that this 
decrease is not a release of the neuropeptide into portal blood that 
triggers the LH surge, because it may occur in the absence of LH release 
e.g. after blockade by barbiturates or SKF 64-139. The release of LHRH 
that initiates or maintains the LH surge may occur after the decline and 
is more likely regulated by both NE and EPI systems.
The pharmacological characterization of neurotransmitters involved 
in ovarian hormone feedback is limited by the selectivity and spe­
cificity of the agents used. In addition to its PNMT-inhibLting 
actions, SKF 64-139 possesses some alpha2-adrenergic blocking effects, 
but those are unlikely to account for its inhibitory actions on LH and 
LHRH surges. First, a non-alpha-blocking PNMT inhibitor also prevents 
ovarian hormone-induced elevation of LH release (92). The rises in LHRH 
and LH concentrations were also inhibited by LY 78335, a PNMT inhibitor 
with little demonstrable alpha-blocking action in vivo (205). Further­
more, PNMT inhibitors do not share the effect of alpha-noradrenergic
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antagonists in disrupting episodic LH release or preventing the eleva­
tion of PRL by estradiol (92). The present results also demonstrate a 
further difference between pharmacological noradrenergic and adrenergic 
antagonists, as the DBH inhibitor FLA-63 abolished the rise in LHRH and 
lowered its concentration, while the PNMT inhibitor did not. Therefore, 
it is more likely that the neuroendocrine effects of LY 78335 and SK & F 
64-139 are due to disruption of EPI rather than NE neurotransmission.
Experiment 2 was designed to examine whether an ovarian hormone 
regimen that elicits an LH surge enhances the activity of NE and EPI 
neurons in the MBH and POA. This and subsequent studies, in which NE 
and EPI activity was of importance, employed the alpha methyltyrosine 
method to determine catecholamine turnover. That is, the degree of 
depletion of a catecholamine after synthesis inhibition with alpha 
methyltyrosine was taken as an index of the activity of that neurotrans­
mitter system. The results also support the hypothesis that central EPI 
neurons participate in the regulation of LH and LHRH release. The 
depletion of MBH EPI induced by the catecholamine synthesis inhibitor 
oMT was potentiated by the estrogen plus progesterone regimen that 
induced an LH surge. It is generally accepted that such enhanced deple­
tion reflects an increased degree of nerve impulse flow in the system 
(185) and these findings, therefore, suggest that there is increased 
activity in medial basal hypothalamic EPI nerve terminals during the LH 
surge induced by the ovarian hormones. Estradiol and progesterone did 
not alter EPI depletion in the POA. Similarly, an earlier report 
observed no changes in EPI turnover in the medial preoptic nucleus
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during the proestrus critical period (108). Although the results are in 
contrast to a recent study reporting increased POA EPI turnover 
coinciding with the proestrus surge of LH (116) the results of the 
present studies suggest that EPI may promote the release of LHRH from 
nerve terminals in the MBH region. This conclusion is supported by the 
demonstration that EPI evokes the release of LHRH from the median 
eminence jji vitro (206).
Because the pharmacological studies suggested that both NE and EPI 
systems may also be activated during the accumulation of LHRH that pre­
cedes the LH surge, the depletion of the catecholamines after aMT treat­
ment were assessed at an earlier time point that approximately corres­
ponds to these events, based on the results from Experiment 1. Consis­
tent with the pharmacological results, EPI depletion was enhanced only 
in the MBH during the earlier period. In addition, the aMT-induced 
decline of NE was maximal at this time in both the POA and MBH. These 
results are consistent with several investigators who have observed 
increased NE turnover in the MBH and POA associated with the proestrus 
or ovarian hormone induced LH surge (104,105,106,110). Moreover, these 
results are also consistent with previous proposals that there are time- 
dependent increases in hypothalamic catecholaminergic activity that 
mediate the effects of ovarian hormones on LHRH and LH release (91).
The results from Experiments 1 and 2 suggest that the ovarian hor­
mones differentially affect NE and EPI systems in different regions of 
the hypothalamus. The elevation of NE turnover by the ovarian hormones 
at 1300 h in both the POA and MBH may possibly reflect the importance of
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NE in the ovarian hormone-induced accumulation of LHRH in the median 
eminence. In contrast to NE, the estradiol plus progesterone treatment 
enhanced EPI turnover only in the MBH but at 1600 h as well as 1300 h. 
Although both NE and EPI seem to be involved in activating LHRH accumu­
lation at 1300 h, EPI may be the neurotransmitter primarily involved in 
promoting the release of LHRH at 1600 h that is directly involved in 
initiating the LH surge.
In summary, the results from Experiments 1 and 2 support the hypo­
thesis that both NE and EPI systems have roles in regulating the secre­
tion of LH. These results indicate that 1) activation of both EPI and 
NE neurons mediates the accumulation of LHRH in the median eminence that 
precedes the ovarian hormone-induced Lh surge; and 2) EPI and NE sys­
tems are also involved in the ovarian hormone-induced LH surge.
The neurochemical mechanisms by which the ovarian hormones modulate 
noradrenergic and adrenergic systems to regulate LH secretion is not 
well understood. The ovarian hormones are apparently not taken up by 
LHRH cell bodies (207). Even though there does appear to be some degree 
of uptake into catecholamine cell bodies (208), the ovarian hormones 
seem to affect catecholamine turnover only in specific regions of the 
brain (110) such as the P0A and MBH, areas that contain catecholamine 
nerve terminals. Thus, the ovarian hormones may affect some process 
that locally controls the turnover of these neurotransmitters at the 
nerve terminals. Experiments 3 and 4- examined the possibility that the 
endogenous opioid neuropeptides may participate in locally modulating 
catecholamine turnover. Therefore, Experiments 3 and 4 were designed to
test whether the opiate antagonist, naloxone, and the opiate agonist, 
morphine, which have well defined effects on gonadotropin secretion, 
alter the activity of NE and EPI neurons in the hypothalamus of ovarian 
hormone treated rats. The results of these studies provide support for 
the hypothesis that opiate effects on LH secretion are mediated by 
alterations in catecholamine neurotransmission. In Experiment 3, admi­
nistration of the opiate antagonist, naloxone, increased LH levels, 
potentiated the decline of NE in the POA and MBH, and enhanced the 
depletion of EPI in the MBH after aMT. These findings suggest that 
naloxone enhances activity in noradrenergic and adrenergic systems that 
innervate the POA and MBH. This conclusion is strengthened by the 
results of previous pharmacological studies demonstrating thatnaloxone- 
induced LH release is prevented by noradrenergic and/or adrenergic syn­
thesis inhibitors (H5, 147). The catecholamine systems that are acti­
vated by the removal of opiate inhibition may, in turn, enhance the 
release of LHRH (92,190).
It is possible that naloxone increases NE and EPI activity by anta­
gonizing the inhibitory influence of an endogenous opioid neuropeptide. 
Opiate alkaloids and neuropeptides depress the release of NE from corti­
cal, cerebellar, and hypothalamic slices in vitro (136,137), and the 
results of Experiment 4- demonstrate that the opiate agonist, morphine, 
may reduce NE and EPI release in discrete hypothalamic regions as well. 
The administration of morphine to ovariectomized rats primed with ova­
rian hormones decreased LH, and also reduced the depletion of NE in the 
POA and MBH and of EPI in the MBH, after aMT, suggesting reduction of
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catecholamine activity during the depression of LH release. Morphine 
also decreased steady-state concentrations of NE in the POA, an effect 
possibly reflecting a decrease in synthesis. This effect was prevented 
in most cases by the coadministration of naloxone, implicating opiate 
receptor involvement in the effect of morphine. Previous studies have 
shown that morphine prevents the ovarian hormone-induced accumulation of 
LHRH in the median eminence (14-1) as well as the release of LHRH into 
pituitary portal blood on proestrus afternoon (138). These results 
indicate that one possible mechanism by which the opiates disrupt LH 
secretion may be through inhibition of hypothalamic noradrenergic and 
adrenergic systems that regulate LHRH synthesis and/or release.
In Experiment 4-, morphine also decreased the aMT induced depletion 
of DA in the MBH. A number of studies have also shown that morphine and 
endogenous opioid peptides such as beta-endorphin reduce the turnover of 
DA in the median eminence and diminish the release of tuberoinfundibular 
DA into hypophysial portal circulation (209). Although confusion 
remains as to the role of these changes in LH secretion, there is more 
evidence linking them to the release of prolactin by morphine (209).
It is interesting to note the similar neuroendocrine and neuro- 
chemical actions of naloxone and progesterone. Both stimulate LH 
release in ovariectomized, estrogen-primed rats and these effects are 
dependent upon catecholaminergic neurotransmission (14-1,14-5,147). More­
over, both progesterone and naloxone stimulate the otMT-induced depletion 
of EPI in the MBH, but not POA, and of NE in the POA and MBH. These 
observations are therefore consistent with the hypothesis that one
aspect of ovarian hormone positive feedback may involve removal of the 
inhibitory influence of an endogenous opioid system over catecholamine 
release. Similarly, morphine may stimulate the opioid receptors for 
such a system that are located on NE and EPI nerve terminals.
Progesterone and naloxone differ, however, in the time course of 
these effects. Progesterone may require several hours to stimulate LH 
release if the hormone is acting via classic steroid receptor mecha­
nisms, involving genomic expression, that result in depression of activ­
ity of an endogenous opioid neuropeptide system, and subsequent stimu­
lation of catecholamine release. Presumably, the opiate antagonist, 
naloxone, stimulates LH and catecholamine release with shorter latentcy 
because this drug directly reduces endogenous opioid neurotranmission, 
bypassing the steroid receptor system.
A number of recent studies have attempted to define what changes, 
if any, occur in brain, pituitary, and plasma beta-endorphin concentra­
tions in naturally cycling animals and if these pools of beta-endorphin 
are responsive to ovarian hormone treatment. An initial report noted 
that median eminence beta-endorphin concentrations increase while 
arcuate levels of beta-endorphin decrease on proestrous afternoon 
(196). However, hypothalamic beta-endorphin concentrations do not 
appear to differ from diestrus to proestrus (197) and a more detailed 
analysis of beta-endorphin content in hypothalamic nuclei during the 
estrous cycle revealed a significant increase in arcuate beta-endorphin 
levels during proestrus (198).
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Thus, attempts to relate changes In beta-endorphin concentrations 
in the hypothalamus with pituitary function have been inconclusive and 
require further investigation.
Beta-endorphin levels appear to vary in hypophyseal portal blood 
during the menstrual cycle (199), being high during the follicular and 
luteal phase and virtually undetectable at menstruation or after long 
term ovariectomy. These results would suggest that when ovarian hormone 
concentrations are low, such as after ovariectomy or during menstrua­
tion, hypothalamic beta-endorphin release is correspondingly low (199). 
These results are interesting in view of other reports noting naloxone's 
inability to stimulate LH release at times when ovarian hormone concen­
trations are low, such as after gonadectomy (200), during the early fol­
licular phase of the menstrual cycle in normal women (201,202), or in 
post-menopausal women (203). Conversely, the opiate peptide FK 33-824- 
fails to inhibit LH release one week after gonadectomy (200). Thus, a 
great deal of evidence exists to support a physiological relationship 
between the ovarian hormones and the endogenous opioid peptides in the 
regulation of the pituitary gonadotropin secretion.
In summary, the results from Experiment 3 and 4- support the hypo­
thesis that the ovarian hormones produce their stimulatory feedback 
effects on LH secretion by altering the activity of an inhibitory endo­
genous opioid neuropeptide system which, in turn, regulates the release 
of NE and EPI. These catecholamines are then able to stimulate LHRH, 
and subsequently, the LH surge.
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A scenario, virtually identical to the hypothesis discussed above, 
has, in fact, been recently reported (91). This proposed role for the 
opioid neuropeptides is complemented by a very similar role in the nega­
tive feedback effects of estradiol in female rats (211) and testosterone 
in male rats (210). In both of these cases it is evisioned that the 
hormone (either estradiol or testosterone) activates an endogenous opi­
oid peptide system that, in turn, inhibits LH secretion (210,211). In 
the model employed in these studies, progesterone may act to physiolo­
gically reverse these negative feedback effects of estradiol in order to 
trigger the preovulatory release of LH.
Few studies have addressed the issue of which endogenous opioid 
peptide(s) the ovarian hormones interact with to regulate LH release.
The evidence presently available suggests that beta-endorphin and/or 
dynorphin peptide may mediate these ovarian hormone effects. Although 
met-enkephalin levels are responsive to chronic estrogen treatment (212) 
in male rats, hypothalamic concentrations of met-enkephalin do not 
appear to fluctuate during the estrous cycle (213). Perhaps more impor­
tantly, antisera against beta-endorphin, and to a lesser extent, anti­
sera against dynorphin 1-13 increase LH release when injected into the 
MBH of immature female rats (214). In contrast, antiserum against met- 
enkephalin do not affect LH release in this model (214). A role for 
dynorphin in the control of LH release is further supported by the find­
ing that bremazocine, a benzomorphan compound selective for kappa recep­
tors, is more potent than morphine as an inhibitor of LH release (215). 
Therefore, an opioid peptide of the beta-endorphin and/or dynorphin
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family may mediate ovarian hormone effects on gonadotropin secretion. 
However, only more intensive research of all the opioid neuropeptides, 
including met-enkephalin, will clearly answer this important question.
As has been detailed in the Introduction of this dissertation, GABA 
may also be considered a candidate for a neuromodulatory role in locally 
controlling hypothalamic catecholamine activity and pituitary LH secre­
tion. Therefore, Experiments 5 and 6 were designed to examine the 
effects of GABA agonists and antagonists on LH secretion under a variety 
of endocrine conditions and also to test whether GABA agonists depress 
activity of NE and EPI neurons after synthesis inhibition in discrete 
regions of the hypothalamus. The results of Experiment 5 and 6 raise 
the possibility that a GABA system exists in the hypothalamus capable of 
inhibiting adenohypophyseal LH secretion, perhaps by depressing activity 
in central NE and EPI neurons. Administration of the GABA agonists, 
baclofen and muscimol, prevented the LH surge in rats induced by the 
sequential pretreatment of estradiol plus progesterone. Maximal inhibi­
tion was reached when a second injection of baclofen or muscimol was 
given 4 h after the first. The effect of the GABA agonists to disrupt 
the LH surge appears to occur in the brain, as neither baclofen nor mus­
cimol affected the release of LH in response to administration of syn­
thetic LHRH.
Baclofen and muscimol also tended to depress LH levels in ovariec- 
tomized, hormonally untreated rats, an effect that is more pronounced 
following central administration of GABA or muscimol (175). It is 
unclear why the GABA antagonist, bicuculline, potentiated this effect,
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although it is possible that under these circumstances, a stimulatory 
GABA component may be unmasked (172).
The barbiturate, phenobarbital, has a well known inhibitory effect 
on the LH surge (192, 193, 194). Because phenobarbital appears to 
enhance the binding of GABA to its receptor and also enhances Cl ion 
conductance, it was possible that the barbiturate effect on LH was medi­
ated by GABA systems. This, however, appears not to be the case as the 
GABA antagonist, bicuculline, did not prevent phenobarbital's blockade 
of the LH surge. Barbiturates may therefore directly affect catechola­
mine transmission to disrupt LH release (193, 194).
The results from Experiment 6 provide further evidence as to pos­
sible sites and mechanisms of action of this inhibitory GABA effect on 
LH release. As demonstrated in Experiment 2 and 5 aMT produced signifi­
cant decreases of NE in the POA and of NE, EPI, and DA in the MBH of 
animals pretreated with estradiol followed by progesterone. Administra­
tion of the GABA agonists, baclofen and muscimol, produced similar 
effects on catecholamine activity as both GABA agonists significantly 
reduced steady state levels and blunted the aMT-induced decline of NE in 
the POA and of both NE and EPI in the MBH. In contrast, the GABA 
agonist did not affect the levels or depletion of DA in the MBH. These 
results suggest that noradrenergic and adrenergic neurotransmission in 
these areas was reduced by GABA stimulation, while DA activity was 
unaffected. Previous reports and the results from Experiments 1-4 have 
demonstrated the importance of NE and EPI activity for the ovarian 
hormone-induced rise in median eminence LHRH and the subsequent LH surge
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(91, 190). GABA systems may therefore disrupt LH release by depressing 
activity in the NE and EPI nerve terminals innervating the POA and MBH 
that regulate these events.
Several lines of evidence support such a role for GABA. GABA 
depresses NE release in brain and from peripheral nerves via actions at 
a receptor subtype different from classical postsynaptic receptor (167, 
168). Pharmacological characterization of this GABA B receptor reveals 
that 1) baclofen is a potent agonist at this receptor subtype, but not 
at the postsynaptic GABA A receptor (168); 2) muscimol also possesses 
some GABA B as well as GABA A activity (154, 161); 3) the GABA B is 
insensitive to antagonism by bicuculine (159, 160). The actions of 
these drugs on the GABA B receptor therefore closely parallel their 
actions on LH release. Interestingly, bicuculline, in a dose known to 
antagonize GABA A receptors (160), failed to block the inhibitory effect 
of muscimol on LH release. This raises the possibility that some GABA A 
effects may contribute to muscimol's depression of LH release. In other 
studies, the selective GABA A agonist, Thip (4,5,6,7-tetrahydroisoxazole 
(5,5-6) pyridin-3-ol) either failed to block or had inconsistent effects 
on LH release, providing further support for GABA B mediation of bac­
lofen and muscimol effects on LH secretion and catecholamine activity.
In contrast to the GABA A-mediated opening of chloride ion channels 
in postsynaptic membranes (149), B receptors have recently been linked 
to inhibition of calcium influx in presynaptic nerve terminals (155,
156, 157). This mechanism, therefore, could possibly account for the 
lowering by baclofen and muscimol of NE and EPI concentrations as well
as the blockade of the aMT-induced depletion of these catecholamines 
observed in Experiment 6. The activity of tyrosine hydroxylase, the 
rate limiting enzyme in catecholamine synthesis, is increased by calcium 
in noradrenergic neurons (216), and activation of GABA B receptors by 
baclofen and muscimol to effectively diminish calcium conductance could 
thus reduce nerotransmitter synthesis and decrease steady state levels 
of the catecholamines. Moreover, it is well established that increased 
intracellular calcium is essential for the release of catecholamines and 
other neurotransmitters (217). The depression of calcium influx by 
stimulation of GABA B receptors might therefore reduce NE and EPI 
release and consequently, the decline of these catecholamines after 
inhibition of synthesis, an effect that depends on the release of 
catecholamine release (185).
The hypothesis of GABA B receptors located on NE and EPI nerve ter­
minals also receives support from the recent demonstration that a subpo­
pulation of GABA B receptors is associated with cortical noradrenergic 
nerve terminals (21B). The regional and neurochemical specificity of 
the effects of GABA agonists on catecholamine activity in Experiment 6 
is consistent with Experiments 2-4 which found that NE in both the POA 
and MBH is responsive to treatments with ovarian hormones and opiate 
drugs, while the EPI systems are affected only in the MBH. The absence 
of an effect of baclofen on MBH DA activity has also been observed pre­
viously (219).
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GABAergic suppression of central NE activity has also been demons­
trated using ovariectomized rats (173, 174), and on the basis of such
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effects it has been proposed that such a localized control mechanism may 
contribute to the inhibitory effects of estrogen on LH release (173, 
174). Although few studies have correlated ovarian hormonal effects on 
LH with changes in central GABA activity, a recent report (175) found 
that an estrogen treatment that reduced LH also increased GABA turnover 
while decreasing NE turnover in the medial preoptic area. Moreover, 
the GABA synthetic enzyme, GAD, is responsive to estradiol treatment 
(178) and hyperprolactinemia, which suppresses both LH release and NE 
activity (220), also increased GAD activity (177) and GABA turnover 
(221). It is interesting, in view of these reports, to note that some 
GABA neurons in the preoptic area accumulate estradiol (176).
In summary, the results from Experiments 5 and 6 support that the 
hypothesis that estradiol and progesterone affect activity in intrahypo- 
thalamic GABA systems that regulate ascending catecholamine input to 
LHRH neurosecretory cells to affect LH release. Experiment 7 was 
designed to examine whether a GABA agonist, which blocks the LH surge, 
also prevents the accumulation of LHRH in the median eminence induced by 
administration of stiulatory estradiol plus progesterone regimen.
As observed in Experiment 1, and reported previously (190), admin­
istration of progesterone to estradiol-primed rats elicits a significant 
increase in median eminence LHRH concentrations at 1100 h. LHRH concen­
trations decreased significantly at 1300 and 1400 h and did not change 
significantly thereafter. Treatment of ovarian hormone-primed rats with 
baclofen, in a dose that markedly suppressed the LH surge, had a dif­
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ferent pattern of effects on LHRH levels. Levels of LHRH were increased 
at the 1100 h time point but did not change significantly thereafter.
In fact, LHRH concentrations were higher at every time point in 
baclofen-treated rats as compared to control animals although only the 
1400 h time point reached statistical significance. Thus, it appears 
that baclofen allows progesterone to stimulate LHRH accumulation in the 
median eminence, yet prevents the subsequent decline in LHRH levels.
The result that in baclofen-treated rats LHRH did not decrease 
significantly after peaking at 1100 h, and that levels at 1400 h were 
significantly higher than controls, may possibly reflect a decrease in 
LHRH release. An effect of baclofen to decrease LHRH release would be 
consistent with the evidence presently available that baclofen reduces 
calcium conductance in presynaptic nerve terminals (155, 156, 157) 
andsuch a mechanism has been suggested to account for baclofen's 
depression of monoamine release in the brain (154, 168) and periphery 
(159, 164, 167).
Experiment 8 was designed to test whether baclofen reverses the 
stimulatory effects of naloxone on LH release and catecholamine activity 
and also to examine whether nalmefene prevents the blockade of the LH 
surge produced by baclofen. The results from Experiment 8 provide 
preliminary evidence for parallel, independent modulation of LH 
secretion and hypothalamic catecholamine activity by GABA and opioid 
peptides. In the first study of Experiment 8, pretreatment of 
estradiol-primed rats with baclofen failed to prevent the enhancement of
LH by naloxone. In addition, the GABA agonist failed to reverse 
naloxone's enhancement of NE or EPI depletion in the MBH induced by 
aMT. These results therefore suggest that the effects of naloxone on 
LH release and catecholamine activity are not due to interruption of 
opioid-GABA links. That is, opioid neuropeptides do not appear to 
stimulate the activity of central GABAergic neurons in order to affect 
hypothalamic catecholamine activity and pituitary LH release.
Experiment 8b was designed to test whether the long acting opiate 
antagonist, nalmefene, could, when administered simultaneously with 
baclofen, reverse the GABA agonist's blockade of the LH surge. In this 
study, treatment with nalmefene could not prevent the blockade by 
baclofen of the ovarian hormone-induced LH surge. These results thus 
suggest that baclofen does not disrupt LH secretion by enhancing an 
opioid peptide inhibitory influence over LH release. Moreover, further 
preliminary evidence is then provided in support of two parallel yet 
independent intrahypothalamic systems that regulate gonadotropin 
secretion and hypothalamic catecholamine activity.
The mechanisms through which NE and EPI act in mediating ovarian 
hormone effects on LHRH and LH release have been partially 
characterized. The majority of studies have implicated alpha-adrenergic 
(but not beta-adrenergic) receptors in NE and EPI actions (97, 222). 
Several recent studies suggest that these alpha-receptors may be of the 
alpha 1 type, presumably post synaptic (89, 116, 222). For example, 
phenylephrine (alpha 1 agonist) and clonidine (alpha 2 agonist) both
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increase LH release in ovariectomized rats primed with estrogen and pro­
gesterone (89). The preovulatory (116) or estrogen-induced LH surge 
(222) is blocked by the alpha 1 antagonists prazosin and phenoxybenza- 
mine (116). Although both alpha 1 and alpha 2 receptors seem to be 
involved, these results provide preliminary support for a primary role 
for alpha 1-adrenergic receptors in the stimulation by noraderenrgic and 
adrenergic systems of LHRH and LH.
The ovarian hormones may regulate monoamine neurotransmission 
through mechanisms other than those affecting synthesis and release.
For example, minor effects of ethinyloestradiol to decrease NE re-uptake 
in the hindbrain have been reported (223). Also, enzymes involved in 
monoamine degradation, such as type A monoamine oxidase, appear to be 
responsive to ovarian hormone treatment (224). Ovarian hormones may 
also modulate monoamine neurotransmission postsynpatically, e.g. by 
affecting the quantity or affinity of neurotransmitter receptors (59). 
However, although ovarian hormones effects on neurtransmltter re-uptake, 
degradation, and receptor quantity may participate in the regulation of 
reproductive function, these mechanisms do not account for discrete 
effects of estradiol and progesterone to affect monoamine turnover only 
in specific regions of the brain. For this reason, it has been proposed 
that the ovarian hormones may affect the activity of neuroregulatory 
substances in the hypothalamus that modulate catechoamine activity and 
anterior pituitary LH secretion.
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SUMMARY
Previous research has demonstrated the importance of monoaminergic 
neurons in mediating the stimulatory feedback effects of the ovarian 
hormones on hypothalamic LHRH concentrations and adenohypohyseal LH 
secretion. Results from Experiments 1 and 2 strongly suggest that brain 
epinephrine, in addition to norepinephrine, may mediate a portion of 
ovarian hormone effects on LHRH and LH.
The stimulatory feedback effects of estradiol and progesterone 
appear to be exerted, at least in part, through activation of POA and 
MBH noradrenergic and MBH adrenergic systems. These neuro-chemical 
changes then seem to facilitate LHRH, and subsequently LH, release.
The neurochemical mechanisms have not been established for these 
discrete ovarian hormone feedback actions on NE and EPI neurotransmis­
sion. Because estradiol and progesterone appear to alter NE and EPI 
turnover primarily in areas containing the nerve terminals for these 
neurotransmitters, the possibility that the ovarian hormones affect that 
activity of neuromodulatory substances was addressed. Results from 
Experiments 3-7 support the concept that the ovarian hormones produce 
their positive feedback effects, in part by reducing activity in hypo­
thalamic opioid neuropeptide and GABA neurons which, in turn, dlsinhibit 
stimulatory NE and EPI inputs to LHRH neurons. This facilitation of 
LHRH release would allow the subsequent LH surge to occur.
Results from Experiment 8 provide preliminary evidence that these 
regulatory effects of opiates and GABA are actions of parallel,
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